Bio X Cell

Bio X Cell(BXC)社は、in-vivo/in-vitro実験用抗体の信頼できるサプライヤーです。アメリカのボストン近郊、ニューハンプシャー州レバノンにあり、1997年から生物医学研究用のモノクローナル抗体を生産しています。BXC社の目的は、高品質の抗体を優れた価格で提供し、優れた顧客サービスでバックアップすることで、科学的発見とイノベーションの推進を促進することです。そのため、in vivo の前臨床研究に必要な大量の、十分に特徴付けられた抗原と新規抗原の両方を標的とする、防腐剤や安定剤を含まない超高純度の低エンドトキシン抗体の製造に取り組んでいます。25年の経験に裏打ちされた、in vivo用モノクローナル抗体の多種のカタログ製品を高品質、低価格で提供します。
当社は、Bio X Cell社の正規日本代理店です。
Bio X Cell

 


 

 

 


 

価格表

価格表(通常・アカデミック): 2024年10月(PDFファイル)
*為替変動に伴い価格を見直しました。
*価格表の閲覧にパスワードが必要となりますので、お問合せください。
*ご注文(配送)ごとに取扱手数料2.5万円(送料・通関手数料等含む・税別)を申し受けます。

 


 

アカデミックプライス適用申込書

アカデミックプライス適用申込書フォーム: 大学等、非営利組織に所属のユーザーはアカデミックプライスが適用されますので、注文時にこちらの申込書をご提出ください。(Wordファイル)

 


 

新製品

品番 品名 クローン Isotype
BE0038 InVivoMAb anti-mouse CD11c N418 IgG2
BE0431 InVivoMAb anti-Zika virus E protein DIII-LR ZV-67 IgG2c, κ
BE0432 InVivoMAb anti-Dengue virus type 2 E protein DIII DV2-96 IgG2c, κ
BE0433 InVivoMAb anti-Eastern equine encephalitis virus E2 protein EEEV-3 IgG2c, κ
BE0434 InVivoMAb anti-Powassan virus E protein POWV-63 IgG2c, κ
BE0435 InVivoMAb anti-Venezuelan equine encephalitis virus E2 protein VEEV-57 IgG2c, κ
BE0436 InVivoMAb anti-human VISTA GG8 IgG1, κ
BE0437 InVivoMAb anti-Dengue virus type 4 E protein DIII DV4-E88 IgG2c, κ
BE0438 InVivoMAb anti-SARS-CoV-2 S protein (RBD) SARS2-38 IgG1, κ
BE0439 InVivoMAb anti-rat CD4 W3/25 IgG1, κ
BE0440 InVivoMAb anti-mouse CXCL10 (IP-10) 1F11 IgG
BE0441 InVivoMAb anti-human IL-10 JES3-19F1 IgG2a, κ
CP179 RecombiMAb HIS human IgG1 F(ab) isotype control, anti-hen egg lysozyme N/A-CP179 IgG1, κ
CP180 RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme N/A-CP180 IgG2, κ
CP181 RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme N/A-CP181 IgG4, κ
CP183 RecombiMAb human IgG4 (S228P/R409K) isotype control, anti-hen egg lysozyme N/A-CP183 IgG4, κ
SIM0033 InVivoSIM anti-human TIGIT (Tiragolumab Biosimilar) Tiragolumab IgG1, κ
SIM0034 InVivoSIM anti-human CD38 (Daratumumab Biosimilar) Daratumumab IgG1, κ
SIM0035 InVivoSIM anti-human CD25 (IL-2Rα) (Daclizumab Biosimilar) Daclizumab IgG1, κ
SIM0036 InVivoSIM anti-human TSLP (Tezepelumab Biosimilar) Tezepelumab IgG2, λ
SIM0037 InVivoSIM anti-human PD-1 (Cemiplimab Biosimilar) Cemiplimab IgG4, κ
SIM0038 InVivoSIM anti-human PD-1 (Tislelizumab Biosimilar) Tislelizumab IgG4, κ

*2024年7月5日追加 

 


 

製品カテゴリー

*Bio X Cell社サイトへリンクします

In Vivo Antibodies 保存剤も、安定剤、キャリアタンパク質も無添加の、in vivo 研究用に特別に調整された抗体です。
Isotype Controls 抗体特異的シグナルを明確に識別するin vivo投与用のアイソタイプ コントロールです。
InVivoSIMTM Antibodies 薬物の生物学的影響を研究できる手頃な価格の研究グレードのバイオシミラー モノクローナル抗体です。
RecombiMAbTM Antibodies 当社の組換えモノクローナル抗体を使用して、マウスモデルまたはヒト化マウスモデルの免疫原性を低減します。
InVivoMAbTM Antibodies 高品質で高純度の抗体を使用して、in vivo および in vitro アプリケーションの成功を推進します。
InVivoPlusTM Antibodies あらゆる研究機関の生体内研究に必要な厳しい要求と厳格な基準を満たします。
InVivoPureTM Dilution Buffers in vivo 用途向けに特別に配合およびテストされたバッファーにより抗体の安定性を維持します。
Fusion Proteins 超低エンドトキシンレベルの融合タンパク質を使用して、受容体とリガンドの相互作用を調査します。
ReadyTagTM Antibodies ダウンストリームウェスタンブロットやELISAなどのために、in vivoで組換えタンパク質タグに確実に結合します。

 

 


 

製品説明・参考情報

InVivoMAb™ vs. InVivoPlus™ InVivoMAb™とInVivoPlus™ の違い
Biosimilar Antibodies 研究グレードのバイオシミラー モノクローナル抗体のInVivoSIM™について 
Recombinant Antibodies 組換え抗体 RecombiMAb™ モノクローナル抗体について
Cell Depletion Antibodies in vivo用のマウス細胞特異的細胞除去抗体について
Immune Checkpoint Antibodies 免疫チェックポイント経路を標的とする様々な抗体について
Choosing Anti-PD-1 Antibodies 研究に適切な抗 PD-1 抗体を選択する方法
Choosing Isotype Controls in vivo 実験に適切なアイソタイプ コントロールを選択して使用する方法
Antibody Structure 抗体の構造と分類について

 


 


よくあるご質問

Q1. in-vivoの研究に使えますか?
A1. お使いになれます!
Q2. 保存料は入ってますか?
A2. 保存料は入っておりません。
Q3. 在庫はありますか?納期はどれぐらいですか?
A3. 基本的にメーカー在庫はありますが、国内在庫は置いておりません。納期は、ご注文から2~3週間程度頂いてます。早ければ、1週間程度でお納めすることもございます。
Q4. InVivoMabとInVivoPlusの違いは?
A4. InVivoPlusはより厳しい品質を求められる研究に適しています。エンドトキシンの濃度は、InVivoMabが<2EU/mg、InVivoPlusが<1EU/mg です。詳細は下記の比較表をご覧ください。
Q5. 参考文献はありますか?
A5. メーカーの製品概要ページよりご参照ください。”References”の文字をクリックすると一覧が表示されます。
Q6. 1mlサイズの物が欲しいのですが?
A6. BXC社製品は、mg単位での容量となっております(ロットによってタンパク濃度が異なるため)。お手元の製品と同じサイズの物がご入用の場合は、ラベルまたはデータシートの”Total protein”の値をご確認ください。(各製品の容量は価格表をご参照ください。)
Q7. 国立の研究所ですが、大学向け価格で買えますか?
A7. 価格表には便宜上、「大学向け」と記していますが、大学及び非営利組織向けの価格となりますので、国公立の研究所・病院などは大学向け価格で販売しております。ご注文の際には、アカデミックプライス適用申込書を都度ご提出ください。なお、代理店経由での販売も致しております。
Q8. 数種類、または複数本買う場合、手数料はどうなりますか?
A8. 一まとめのご注文ごとに1回分のお手数料をご請求いたします。1度のご注文が1本でも、10本でも同じお手数料になりますので、まとめてのご注文をお勧めいたします。
Q9. 抗体の推奨コントロールはどれになりますか?
A9. メーカーの製品概要ページに掲載がございます。「Recomended Isotype Control(s)」をご覧ください。
Q10. 抗体の保存期間はどのくらいですか?
A10. 製品データシートに記載されている条件で抗体を保管した場合、受領日から1年間安定しています。
Q11. BXC社の製品はカルタヘナ法に該当しますか?
A11. BXC社のすべての製品はカルタヘナ法に該当しません。
Q12. 抗体 100mgを1本注文したところ、50mgのバイアルが2本届きました。間違えていませんか?
A12. メーカーの在庫状況により包装形態がご注文と異なる場合がございます。包装サイズのご指定はお受け致しかねますので、予めご了承のほどお願い申し上げます。 
例: 100mg x 1本の注文 → 50mg x 1本と25mg x 2本での納品など
Q13. 無償サンプルはありますか?
A13. あいにく無償サンプルの提供はございません。

 


 

InVivoMAb™ vs. InVivoPlus™

Bio X Cell社は、最も人気のある InVivoMAb™ 製品の InVivoPlus™ バージョンを提供しています。 BXC社製品の InVivoPlus™ バージョンは、InVivoMAb™ バージョンと構造的および機能的に同一です。 違いは、あらゆる研究機関の生体内研究に必要な厳しい要求と厳格な基準を満たす、またはそれを超える優れたレベルの品質にあります。

 

  InVivoMAb™  InVivoPlus™
バインディングの検証*
Determined by immunoblot, flow cytometry, or ELISA
未確認 確認済
マウス病原体スクリーニング†
Determined by ultrasensitive real-time PCR
未確認 確認済
抗体凝集スクリーニング
Determined by Size Exclusion Chromatography
未確認 確認済
エンドトキシン
Determined by LAL gel clotting assay
<2EU/mg <1EU/mg
純度
Determined by SDS-PAGE
>95%  >95%
防腐剤、安定剤、キャリアタンパク質不使用 不使用 不使用
in-vivo 研究の適性 適する 適する
品番 BEから始まる BPから始まる

 

*バインディングの検証は、該当するすべての InVivoPlus™ 製品のロットごとに実行されます。 適用されない InVivoPlus™ 製品には、抗原が市販されていない抗体や非反応性アイソタイプ コントロール抗体が含まれます。

†マウス病原体スクリーニングは以下を含みます:
Mycoplasma including M. pulmonis, M. arginini, M. fermentans, M. hominis, M. hyorhinis, M. orale, M. pirum, M. salivarium, M. agassizii, M. cynos and others.
Murine norovirus (MNV), murine parvovirus (MPV) 1, 2, 3, 4, and 5, murine minute virus (MMV/MVM), murine hepatitis virus (MHV), murine reovirus (REO) type 1, 2, and 3, lymphocytic choriomeningitis virus (LCMV), lactate dehydrogenase elevating virus (LDV), murine rotavirus MRV/EDIM), Theiler’s murine encephalomyelitis virus (TMEV), ectromelia virus (ECTRO), hantavirus (HANTA), polyoma virus (POLY), murine adenovirus (detects and differentiates MAD1 and MAD2), sendai virus (SEND), pneumonia virus of mice (PVM), murine cytomegalovirus (MCMV) 1 and 2 (MCMV), and K virus.

 


 

製品一覧

◎製品検索は表の上の検索ボックスをご利用ください。品番のリンクから製品詳細(Bio X Cell社サイト)をご覧いただけます。

新製品品番-最小容量品名クローンイソタイプ報告された用途推奨コントロール品番推奨バッファー品番
BE0000-1MGInVivoMAb anti-mouse CD1d (CD1.1)19G11IgG1in vivo CD1d neutralization, in vitro CD1d neutralizationBE0088IP0070
BE0001-1-1MGInVivoMAb anti-mouse CD3ε145-2C11IgG1in vivo T cell depletion, in vitro T cell stimulation/activation, Immunofluorescence, Flow cytometry, Western blotBE0091IP0070
BE0001-1FAB-10MGInVivoMAb anti-mouse CD3ε F(ab')2 fragment145-2C11 f(ab')2 FragmentsIgG1in vivo T cell depletionBE0091-FABIP0070
BE0001-2-1MGInVivoMAb anti-human CD3OKT-3IgG2a, κin vitro T cell stimulation/activation, in vivo T cell depletion in humanized mice, ex vivo T cell inhibition for xenografts, Flow cytometryBE0085IP0070
BE0002-1MGInVivoMAb anti-mouse CD317A2IgG2b, κin vitro T cell stimulation/activationBE0090IP0070
BE0003-1-1MGInVivoMAb anti-mouse CD4GK1.5IgG2b, κin vivo CD4+ T cell depletion, Flow cytometry, Western blotBE0090IP0065
BE0003-2-1MGInVivoMAb anti-human CD4OKT-4IgG2b, κin vitro T cell stimulation/activation, in vivo CD4+ T cell depletion in humanized mice, Flow cytometry, ImmunoprecipitationBE0086IP0070
BE0003-3-1MGInVivoMAb anti-mouse CD4YTS 177IgG2ain vivo blockade of CD4+ T-cell responses, Western blotBE0089IP0070
BE0004-1-1MGInVivoMAb anti-mouse CD8α53-6.7IgG2a, κin vivo CD8+ T cell depletion, Immunofluorescence, Flow cytometry, Western blotBE0089IP0065
BE0004-2-1MGInVivoMAb anti-human CD8αOKT-8IgG2ain vivo CD8+ T cell depletion in humanized miceBE0085IPT060
BE0005-1MGInVivoMAb anti-human LFA-1α (CD11a)TS-1/22.1.1.13IgG1in vitro LFA-1 neutralizationBE0083IP0070
BE0005-1-1MGInVivoMAb anti-mouse LFA-1α (CD11a)FD441.8IgG2bin vivo LFA-1 neutralizationBE0090IP0070
BE0007-1MGInVivoMAb anti-mouse/human CD11bM1/70IgG2b, κin vivo CD11b neutralization, ILC2 cell purification, Flow cytometryBE0090IP0070
BE0009-1MGInVivoMAb anti-mouse CD18M18/2IgG2a, κin vivo LFA-1 neutralizationBE0089IP0070
BE0011-1MGInVivoMAb anti-mouse CD22Cy34.1IgG1, κin vivo B cell depletion in combination with anti-CD19 (clone 1D3) and anti-rat κ Light Chain (clone MAR 18.5), Flow cytometry, ImmunoprecipitationBE0083IP0070
BE0012-1MGInVivoMAb anti-mouse CD25 (IL-2Rα)PC-61.5.3IgG1, λin vivo regulatory T cell depletion, Flow cytometryBE0088IP0070
BE0014-1MGInVivoMAb anti-human CD25 (IL-2Rα)7G7B6IgG2ain vivo regulatory T cell depletion in humanized mice, Immunoprecipitation, ImmunofluorescenceBE0085IP0070
BE0015-1-1MGInVivoMAb anti-mouse CD2837.51IgG2in vitro T cell stimulation/activation, in vivo CD28 blockadeBE0087IPT060
BE0016-2-1MGInVivoMAb anti-mouse CD40FGK4.5/FGK45IgG2ain vivo CD40 activation, in vitro B cell stimulation/activationBE0089IP0070
BE0017-1-1MGInVivoMAb anti-mouse CD40L (CD154)MR-1IgGin vivo blocking of CD40/CD40L signaling, in vitro blocking of CD40/CD40L signaling, Western blotBE0091IP0070
BE0019-1MGInVivoMAb anti-mouse CD45RBMB23G2 (HB220)IgG2a, κin vivo anti-CD45RB_mediated tolerance induction, in vivo pre-mNK cell depletionBE0089IP0070
BE0019-1-1MGInVivoMAb anti-human CD47B6.H12IgG1, κin vitro CD47 neutralization, in vivo CD47 neutralization in human tumor xenograft models or humanized mice, Flow cytometryBE0083IP0070
BE0020-1-1MGInVivoMAb anti-mouse CD54 (ICAM-1)YN1/1.7.4IgG2b, κin vivo ICAM-1 neutralization, Immunohistochemistry (frozen), ELISABE0090IP0070
BE0020-2-1MGInVivoMAb anti-human CD54 (ICAM-1)R6-5-D6IgG2ain vitro T cell stimulation/activation, ImmunofluorescenceBE0085IP0070
BE0021-1MGInVivoMAb anti-mouse L-Selectin (CD62L)Mel-14IgG2a, κin vivo CD62L neutralizationBE0089IP0070
BE0022-1MGInVivoMAb anti-mouse CD70FR70IgG2b, κin vivo CD70 blockade, in vitro CD70 blockade, Flow cytometryBE0090IP0070
BE0023-1MGInVivoMAb anti-human CD71OKT-9IgG1, κImmunohistochemistry (frozen), Immunofluorescence, Flow cytometryBE0083IP0070
BE0024-1MGInVivoMAb anti-mouse CD80 (B7-1)16-10A1IgG2in vivo CD80 blockade, Flow cytometryBE0091IP0080
BE0025-1MGInVivoMAb anti-mouse CD86 (B7-2)GL-1IgG2a, κin vivo CD86 blockade, Flow cytometryBE0089IP0070
BE0026-1MGInVivoMAb anti-mouse CD103M290IgG2a, κin vivo CD103 neutralization, Immunofluorescence, Flow cytometryBE0089IP0070
BE0027-1MGInVivoMAb anti-mouse CD106 (VCAM-1)M/K-2.7IgG1, κin vivo VCAM-1 neutralization, ImmunofluorescenceBE0088IP0070
BE0028-1MGInVivoMAb anti-mouse ICOSL (CD275)HK5.3IgG2a, κin vivo ICOSL neutralizationBE0089IP0070
BE0029-1MGInVivoMAb anti-mouse IFNγR (CD119)GR-20IgG2a, κin vivo IFNγR neutralization, in vitro IFNγR neutralizationBE0089IP0070
BE0031-1MGInVivoMAb anti-mouse OX40 (CD134)OX-86IgG1, κin vivo OX40 activation, in vitro OX40 activation, Western blotBE0088IP0070
BE0032-1MGInVivoMAb anti-mouse CTLA-4 (CD152)UC10-4F10-11IgGin vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Flow cytometry, Western blotBE0091IP0065
BE0033-1-1MGInVivoMAb anti-mouse OX40L (CD134L)RM134LIgG2b, κin vivo blocking of OX40/OX40L signaling, in vitro OX40L neutralizationBE0090IP0070
BE0033-2-1MGInVivoMAb anti-mouse PD-1 (CD279)J43IgGin vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Western blotBE0091IP0065
BE0034-1MGInVivoMAb anti-mouse LPAM-1 (Integrin α4β7)DATK32IgG2a, κin vivo Integrin α4β7 neutralization, Flow cytometryBE0089IP0070
BE0035-1MGInVivoMAb anti-mouse MAdCAM-1MECA-367IgG2a, κin vivo MAdCAM-1 neutralization, ImmunofluorescenceBE0089IP0070
BE0036-1MGInVivoMAb anti-mouse NK1.1PK136IgG2a, κin vivo NK cell depletion, Flow cytometryBE0085IP0070
BE0039-1MGInVivoMAb anti-mouse/human CD44IM7IgG2b, κin vivo CD44 neutralization, in vitro CD44 neutralizationBE0090IP0070
BE0040-1MGInVivoMAb anti-rat CD28JJ319IgG1, κin vitro T cell stimulation/activation, Flow cytometryBE0083IP0070
BE0042-1MGInVivoMAb anti-mouse IL-2JES6-5H4IgG2b, κin vivo IL-2 neutralization, in vitro IL-2 neutralization, in vivo IL-2 receptor stimulation (as a complex with IL-2), ELISPOT, Flow cytometryBE0090IP0070
BE0045-1MGInVivoMAb anti-mouse IL-411B11IgG1, κin vivo IL-4 neutralization, in vitro IL-4 neutralization, in vivo IL-4 receptor stimulation (as a complex with IL-4), Flow cytometry, Western blotBE0088IP0070
BE0046-1MGInVivoMAb anti-mouse IL-6MP5-20F3IgG1, κin vivo IL-6 neutralization, in vitro IL-6 neutralizationBE0088IP0070
BE0047-1MGInVivoMAb anti-mouse IL-6R15A7IgG2b, κin vivo blocking of IL-6/IL-6R signaling, in vitro blocking of IL-6R signalingBE0090IP0070
BE0048-1MGInVivoMAb anti-mouse/human IL-7M25IgG2bin vivo IL-7 neutralization, in vivo IL-7 receptor stimulation (as a complex with IL-7)BE0086IP0070
BE0049-1MGInVivoMAb anti-mouse IL-10JES5-2A5IgG1, κin vivo IL-10 neutralization, in vitro IL-10 neutralizationBE0088IP0070
BE0050-1MGInVivoMAb anti-mouse IL-10R (CD210)1B1.3AIgG1, κin vivo blocking of IL-10/IL-10R signaling, in vitro blocking of IL-10R signaling, Flow cytometry, Western BlotBE0088IPT065
BE0051-1MGInVivoMAb anti-mouse IL-12 p40C17.8IgG2a, κin vivo IL-12p40 neutralization, p40 affinity chromatography, Immunoprecipitation, ELISA, Flow cytometry, Western blotBE0089IP0070
BE0052-1MGInVivoMAb anti-mouse IL-12R1-5D9IgG2ain vivo IL-12 neutralization, in vitro IL-12 neutralizationBE0089IP0070
BE0054-1MGInVivoMAb anti-mouse IFNγR4-6A2IgG1, κin vivo IFNγ neutralization, in vitro IFNγ neutralizationBE0088IP0080
BE0057-1MGInVivoMAb anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-β1D11.16.8IgG1, κin vivo TGFβ neutralization, in vitro TGFβ neutralization, Western blotBE0083IP0070
BE0058-1MGInVivoMAb anti-mouse TNFαXT3.11IgG1in vivo TNFα neutralization, in vitro TNFα neutralization, Western blotBE0088IP0080
BE0059-1MGInVivoMAb anti-mouse ICOS7E.17G9IgG2b, κin vivo blocking of ICOS/ICOSL signaling, Flow cytometryBE0090IP0080
BE0060-1MGInVivoMAb anti-mouse VEGFR-2DC101IgG1, κin vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling, Western blotBE0088IP0070
BE0061-1MGInVivoMAb anti-mouse CD8α2.43IgG2b, κin vivo CD8+ T cell depletion, Western blotBE0090IP0070
BE0062-1MGInVivoMAb anti-mouse/human Integrin β7FIB504IgG2a, κin vivo blocking of integrin β7, Immunoprecipitation, Western blot, Flow cytometryBE0089IP0070
BE0063-1MGInVivoMAb anti-mouse GITRDTA-1IgG2b, λin vivo GITR stimulationBE0090IP0070
BE0065-1MGInVivoMAb anti-mouse IL-7Rα (CD127)A7R34IgG2a, κin vivo blocking of IL-7Rα signaling, Flow cytometryBE0089IP0070
BE0066-1MGInVivoMAb anti-mouse Thy1.2 (CD90.2)30H12IgG2b, κin vivo ILC depletion, in vivo T cell depletion, Western blotBE0090IP0070
BE0067-1MGInVivoMAb anti-mouse B220RA3.3A1/6.1 (TIB-146)Rat IgMin vivo B cell depletion, in vitro B cell negative selectionBE0094IP0070
BE0068-1MGInVivoMAb anti-mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As,I-Ag7)10-3.6.2IgG2c, κin vitro MHC class II I-A blocking, in vitro MHC class II I-A expressing cell negative selectionBE0366IP0070
BE0069-1MGInVivoMAb anti-mouse 2C TCR1B2IgG1Immunofluorescence, Flow cytometryBE0083IP0070
BE0070-1MGInVivoMAb anti-mouse TCR γ/δUC7-13D5IgG, κin vivo TCR γ/δ neutralization, in vitro γ/δ T cell stimulation, in vitro γ/δ T cell purification, Functional assays, Immunoprecipitation, Flow cytometryBE0091IPT060
BE0071-1MGInVivoMAb anti-mouse/human VLA-4 (CD49d)PS/2IgG2b, κin vivo VLA-4 neutralization, in vitro VLA-4 neutralization, Flow cytometryBE0090IP0065
BE0072-1MGInVivoMAb anti-mouse T15 VH and T15 VL regions of IgMAB1-2 (HB33)IgG1, κELISABE0083IP0070
BE0075-1MGInVivoMAb anti-mouse Ly6G/Ly6C (Gr-1)RB6-8C5IgG2b, κin vivo depletion of Gr-1+ myeloid cells, Flow cytometry, Immunohistochemistry (paraffin), Immunohistochemistry (frozen)BE0090IP0070
BE0075-1-1MGInVivoMAb anti-mouse Ly6G1A8IgG2a, κin vivo neutrophil depletion, in vivo MDSC depletion, Immunofluorescence, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Flow cytometryBE0089IP0070
BE0076-1MGInVivoMAb anti-mouse Thy1 (CD90)M5/49.4.1IgG2ain vitro T cell depletionBE0089IP0070
BE0077-1MGInVivoMAb anti-mouse MHC Class I (H-2)M1/42.3.9.8IgG2a, κex vivo blocking of MHC I-dependent interactions, Immunofluorescence, Flow cytometryBE0089IP0070
BE0079-1MGInVivoMAb anti-human MHC Class I (HLA-A, HLA-B, HLA-C)W6/32IgG2a, κFunctional assaysBE0085IP0065
BE0083-1MGInVivoMAb mouse IgG1 isotype control, unknown specificityMOPC-21IgG1, κIP0065
BE0085-1MGInVivoMAb mouse IgG2a isotype control, unknown specificityC1.18.4IgG2a, κIP0070
BE0086-1MGInVivoMAb mouse IgG2b isotype control, unknown specificityMPC-11IgG2b, κIP0070
BE0087-1MGInVivoMAb polyclonal Syrian hamster IgGpolyclonal Syrian hamster IgGIgGIP0070
BE0088-1MGInVivoMAb rat IgG1 isotype control, anti-horseradish peroxidaseHRPN-CP167IgG1, κIP0070
BE0089-1MGInVivoMAb rat IgG2a isotype control, anti-trinitrophenol2A3IgG2a, κIP0065
BE0090-1MGInVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyaninLTF-2-CP166IgG2b, κIP0070
BE0091-1MGInVivoMAb polyclonal Armenian hamster IgGpolyclonal Armenian hamster IgGIgGIP0070
BE0091-FAB-10MGInVivoMAb hamster IgG f(ab')2 fragmentshamster IgG f(ab')2 FragmentsPolyclonalIP0070
BE0092-1MGInVivoMAb polyclonal human IgGpolyclonal human IgGIgGIP0070
BE0093-1MGInVivoMAb polyclonal mouse IgGpolyclonal mouse IgGIgGIP0070
BE0094-1MGInVivoMAb polyclonal rat IgGpolyclonal rat IgGIgGIP0070
BE0096-1MGInVivoMAb recombinant human IgG1 Fchuman Fc-G1IP0070
BE0097-1MGInVivoMAb recombinant mouse IgG2a FcMouse Fc-G2aIP0070
BE0098-1MGInVivoMAb recombinant Flt-3L-Ig (hum/hum)Flt-3L-Ig (hum/hum)BE0096IP0070
BE0099-1MGInVivoMAb recombinant CTLA-4-Ig (hum/hum)CTLA-4-Ig (hum/hum)BE0096IP0070
BE0101-1MGInVivoMAb anti-mouse PD-L1 (B7-H1)10F.9G2™IgG2b, κin vivo PD-L1 blockade, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometry, Western blotBE0090IP0065
BE0102-1MGInVivoMAb anti-mouse TCRβH57-597 (HB218)IgGin vivo T cell depletionBE0091IP0070
BE0104-1MGInVivoMAb anti-mouse MHC Class I (H-2Kd)SF1.1.10 (HB-159)IgG2a, κPurification of MHC peptide complexes, in vivo administration, Flow cytometryBE0085IP0070
BE0106-1MGInVivoMAb anti-LCMV nucleoproteinVL-4IgG2a, κImmunofluorescence, Flow cytometryBE0089IP0070
BE0108-1MGInVivoMAb anti-mouse MHC Class II (I-A/I-E)M5/114IgG2bin vivo MHC II blockade, Functional assays, Immunofluorescence, Western blot, Immunoprecipitation, Flow cytometryBE0090IP0070
BE0110-1MGInVivoMAb anti-mouse 4-1BBL (CD137L)TKS-1IgG2a, κin vivo 4-1BBL blockade, ELISABE0089IP0070
BE0111-1MGInVivoMAb anti-mouse NKG2DHMG2DIgGin vivo NKG2D blockadeBE0091IP0070
BE0112-1MGInVivoMAb anti-mouse PD-L2 (B7-DC)TY25IgG2a, κin vivo PD-L2 blockade, in vitro PD-L2 blockade, Immunohistochemistry (frozen), Flow cytometryBE0089IP0070
BE0113-1MGInVivoMAb anti-mouse TIM-1 (CD365)RMT1-10IgG2a, κin vivo TIM-1 blockadeBE0089IP0070
BE0114-1MGInVivoMAb anti-mouse TIM-2RMT2-29Rat Ig2a, λBE0089IP0070
BE0115-1MGInVivoMAb anti-mouse TIM-3 (CD366)RMT3-23IgG2a, κin vivo TIM-3 neutralization, in vitro TIM-3 blocking, Flow cytometryBE0089IP0070
BE0117-1MGInVivoMAb anti-mouse CD8αYTS 169.4IgG2b, κin vivo CD8+ T cell depletion, Western blotBE0090IP0070
BE0118-1MGInVivoMAb anti-mouse CD8 (Lyt 2.1)116-13.1 (HB-129)IgG2a, κin vivo CD8+ T cell depletion, Flow cytometryBE0085IP0070
BE0119-1MGInVivoMAb anti-mouse CD4YTS 191IgG2b, κin vivo CD4+ T cell depletionBE0090IP0070
BE0120-1MGInVivoMAb anti-swine MHC Class I (SLAd)74-11-10 (HB139)IgG2b, κFlow cytometryBE0086IP0070
BE0121-1MGInVivoMAb anti-mouse MHC Class I (H-2Kb)AF6-88.5.5.3IgG2a, κin vivo administration, Flow cytometryBE0085IP0070
BE0122-1MGInVivoMAb anti-rat Kappa Immunoglobulin Light ChainMAR 18.5IgG2a, κin vivo B cell depletion in combination with anti-CD19 (clone 1D3) and anti-CD22 (clone Cy34.1)BE0085IP0070
BE0123-1MGInVivoMAb anti-human/rat/fish AChRMab35 (TIB-175)IgG1EAMG induction in rats, ImmunofluorescenceBE0088IP0070
BE0124-1MGInVivoMAb anti-mouse CD276 (B7-H3)MJ18IgG1, κin vivo B7-H3 blockade, Flow cytometryBE0088IP0070
BE0125-1MGInVivoMAb anti-mouse Jagged 2HMJ2-1IgGin vivo Jagged 2 neutralizationBE0091IP0070
BE0127-1MGInVivoMAb anti-mouse Delta-like protein 4 (DLL4)HMD4-2IgG, κin vivo DLL4 neutralization, in vitro DLL4 neutralizationBE0091IP0070
BE0129-1MGInVivoMAb anti-mouse Notch4HMN4-14IgG, κin vivo Notch4 blocking, in vitro Notch4 stimulation, Flow cytometryBE0091IP0070
BE0131-1MGInVivoMAb anti-mouse CTLA-4 (CD152)9H10IgGin vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Western blotBE0087IP0070
BE0132-1MGInVivoMAb anti-mouse BTLA (CD272)6A6IgG, κin vivo BTLA stimulation, in vivo BTLA blockadeBE0091IP0070
BE0134-1MGInVivoMAb anti-mouse CD80 (B7-1)1G10IgG2a, κin vivo CD80 blockade, Affinity chromatographyBE0089IP0070
BE0136-1MGInVivoMAb anti-human E-SelectinCL2IgG2a, κFlow cytometryBE0085IP0070
BE0139-1MGInVivoMAb anti-mouse/human/rat v-H-RasY13-238IgG2aImmunoprecipitationBE0089IP0070
BE0140-1MGInVivoMAb anti-mouse MHC Class II (βchain)KL277IgGWestern blotIP0070
BE0143-1MGInVivoMAb anti-rat β-2-Microglobulin4C9IgG1in vitro β2M blockadeBE0083IP0070
BE0144-1MGInVivoMAb anti-rat FcRn heavy chain heterodimers2G3IgG1ELISA, Flow cytometryBE0083IP0070
BE0146-1MGInVivoMAb anti-mouse PD-1 (CD279)RMP1-14IgG2a, κin vivo blocking of PD-1/PD-L signalingBE0089IP0070
BE0147-1MGInVivoMAb anti-mouse CD48HM48-1IgGin vivo CD48 blockade, in vitro CD48 blockingBE0091IP0070
BE0150-1MGInVivoMAb anti-mouse CD191D3IgG2a, κin vivo B cell depletion, in vivo CD19 neutralization, in vitro B cell negative selection, Flow cytometryBE0089IP0070
BE0151-1MGInVivoMAb anti-mouse/human TYRP1/TRP1 (gp75)TA99IgG2a, κin vivo triggering of FcγRs, Immunofluorescence, Flow cytometryBE0085IP0070
BE0152-1MGInVivoMAb anti-mouse MHC Class I (H-2Kk)AF3-12.1.3IgG1in vivo administrationBE0083IP0070
BE0153-1MGInVivoMAb anti-mouse BTLA (CD272)PK18.6IgG1, κin vivo stimulation of BTLA, in vitro stimulation of BTLA, Flow cytometryBE0088IP0070
BE0154-1MGInVivoMAb anti-HIV gp12055-36IgG1, κBE0083IP0070
BE0155-1MGInVivoMAb anti-mouse Delta-like protein 1 (DLL1)HMD1-5IgG, κin vivo DLL1 neutralization, Flow cytometryBE0091IP0070
BE0158-1MGInVivoMAb anti-mouse MHC Class I (H-2Kk, H-2Dk)15-3-1S (HB-13)IgG2a, κin vivo administration, Flow cytometryBE0085IP0070
BE0159-1MGInVivoMAb anti-Influenza A virus NPH16-L10-4R5 (HB-65)IgG2aImmunoprecipitation, Immunohistochemistry (paraffin), in vivo induction of passive immunity to influenza A virus, Western blot, Flow cytometryBE0085IP0070
BE0161-1MGInVivoMAb anti-mouse DR5 (CD262)MD5-1IgG, κin vivo induction TRAIL-mediated apoptosis, in vitro induction TRAIL-mediated apoptosisBE0091IP0070
BE0162-1MGInVivoMAb anti-human Glycophorin A (type M)6A7MIgG1, κin vitro GPA blockadeBE0083IP0070
BE0164-1MGInVivoMAb anti-mouse CTLA-4 (CD152)9D9IgG2bin vivo CTLA-4 neutralization, Western blotBE0086IP0070
BE0165-1MGInVivoMAb anti-mouse Nonclassical MHC Class I molecule Qa-1b4C2.4A7.5H11IgG1Western blot, ImmunofluorescenceBE0083IP0070
BE0166-1MGInVivoMAb anti-mouse Vβ4 TCRKT4IgG2bin vivo administration, Flow cytometryBE0090IP0070
BE0167-1MGInVivoMAb anti-mouse/rat MHC Class II (I-Ek/RT1-D)14-4-4S (HB-32)IgG2a, κin vivo blocking of antigen presentation, Flow cytometryBE0085IP0070
BE0168-1MGInVivoMAb anti-mouse Vγ2 TCRUC3-10A6IgG, κin vivo γδ T cell depletion, Flow cytometryBE0091IP0070
BE0169-1MGInVivoMAb anti-mouse 4-1BB (CD137)LOB12.3IgG1, κin vivo activation of 4-1BBBE0088IP0080
BE0171-1MGInVivoMAb anti-mouse TIM-4RMT4-53IgG2b, κin vivo TIM-4 blockade, in vitro TIM-4 blockade, ImmunofluorescenceBE0090IP0070
BE0172-1MGInVivoMAb anti-mouse MHC Class I (H-2Kb)Y-3IgG2b, κin vivo MHC II blockade, Functional assays, Purification of MHC peptide complexes, Flow cytometryBE0086IP0070
BE0173-1MGInVivoMAb anti-mouse IL-17A17F3IgG1, κin vivo IL-17A neutralizationBE0083IP0070
BE0174-1MGInVivoMAb anti-mouse LAG-3C9B7WIgG1, κin vivo LAG-3 neutralization, in vitro LAG-3 neutralization, Flow cytometry, Western blotBE0088IP0070
BE0175-1MGInVivoMAb anti-mouse CD71 (TfR1)R17 217.1.3/TIB-219IgG2a, κin vivo depletion of CD71+ cellsBE0089IP0070
BE0176-1MGInVivoMAb anti-mouse Kappa Immunoglobulin Light Chain187.1 (HB-58)IgG1, κImmunofluorescenceBE0088IP0070
BE0178-1MGInVivoMAb anti-mouse MHC class II (I-A)Y-3PIgG2a, κin vivo blockade of TCR stimulation, Flow cytometryBE0085IP0070
BE0179-1MGInVivoMAb anti-mouse CD1d (CD1.1)20H2 (HB323)IgG1, κiNKT cell neutralization, in vivo CD1d blockade, Flow cytometryBE0088IP0070
BE0180-1MGInVivoMAb anti-mouse MHC Class I (H-2Kd, H-2Dd)34-1-2SIgG2a, κin vivo activation of APCsBE0085IP0070
BE0181-1MGInVivoMAb anti-mouse IL-99C1IgG2ain vivo IL-9 neutralizationBE0085IP0070
BE0182-1MGInVivoMAb anti-mouse Vβ8 TCRF23.1IgG2a, κFlow cytometryBE0085IP0070
BE0183-1MGInVivoMAb anti-mouse Ter-119TER-119IgG2b, κin vivo administration, in vitro erythrocyte negative selection, Functional assays, Flow cytometryBE0090IP0070
BE0185-1MGInVivoMAb anti-mouse/human/rat CCL2 (MCP-1)2H5IgG, κin vivo CCL2 neutralization, Immunohistochemistry (frozen)BE0091IP0070
BE0186-1MGInVivoMAb anti-mouse PSGL-1 (CD162)4RA10IgG1, κin vivo PSGL-1 blockade, Immunohistochemistry (frozen)BE0088IP0070
BE0187-1MGInVivoMAb anti-rat CD80 (B7-1)3H5IgG1, κin vitro CD80 blockade, Flow cytometryBE0083IP0070
BE0188-1MGInVivoMAb anti-human PD-1 (CD279)J116IgG1, κin vitro PD-1 neutralization, in vivo PD-1 blockade in humanized miceBE0083IP0070
BE0189-1MGInVivoMAb anti-human CD40G28.5IgG1, κin vitro CD40 stimulation, Functional assays, Flow cytometryBE0083IP0070
BE0190-1MGInVivoMAb anti-human CTLA-4 (CD152)BN13IgG2a, κin vitro CTLA-4 neutralization, Flow cytometryBE0085IP0070
BE0191-1MGInVivoMAb anti-mouse RANKL (CD254)IK22/5IgG2a, κin vivo RANKL blockadeBE0089IP0065
BE0192-1MGInVivoMAb anti-human CD11a (LFA-1α)R7-1IgG1Functional assays, Flow cytometryBE0083IP0070
BE0193-1MGInVivoMAb anti-human PD-1 (CD279)J110IgG1, κin vivo PD-1 blockade in humanized mice, Flow cytometryBE0083IP0070
BE0194-1MGInVivoMAb anti-Phosphotyrosine4G10IgG2bELISA, Western blotBE0086IP0070
BE0196-1MGInVivoMAb anti-mouse BTLA (CD272)PJ196IgG1in vivo BTLA blockade, in vitro T cell stimulation/activation, Flow cytometryBE0083IP0070
BE0198-1MGInVivoMAb anti-mouse/human IL-5TRFK5IgG1, κin vivo IL-5 neutralization, in vivo eosinophil depletionBE0088IP0070
BE0199-1MGInVivoMAb anti-mouse IL-4BVD6-24G2IgG1, κELISA, ELISPOT, Flow cytometryBE0088IP0070
BE0200-1MGInVivoMAb anti-mouse Pan-endothelial Cell Antigen (MECA-32)MECA-32IgG2a, κImmunohistochemistry (frozen), Flow cytometry, Western blot, ImmunofluorescenceBE0089IP0070
BE0201-1MGInVivoMAb anti-mouse/human KLRG-12F1IgGFlow cytometryBE0087IP0070
BE0202-1MGInVivoMAb anti-mouse Siglec-H440cIgG2bin vivo administration, Flow cytometryBE0090IP0070
BE0203-1MGInVivoMAb anti-mouse Ly6CMonts 1IgG2ain vivo macrophage depletion (in combination with clodronate liposomes), Flow cytometryBE0089IP0070
BE0204-1MGInVivoMAb anti-mouse CSF15A1IgG1, κin vivo CSF1 neutralizationBE0088IP0080
BE0206-1MGInVivoMAb anti-mouse F4/80CI:A3-1IgG2b, κin vivo Monocyte/Macrophage depletion, Functional assays, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Flow cytometryBE0090IP0070
BE0207-1MGInVivoMAb anti-mouse MHC Class I (H-2Kb) bound to SIINFEKL peptide (OVA residues 257-264)25-D1.16IgG1, κin vivo blocking of Kb -SIINFEKL, Functional assays, Flow cytometryBE0083IP0070
BE0209-1MGInVivoMAb anti-mouse CD73TY/23IgG2a, κin vivo CD73 blockade, in vitro CD73 blockadeBE0089IP0070
BE0210-1MGInVivoMAb anti-mouse BTLA (CD272)8F4IgG1, κFlow cytometryBE0083IP0070
BE0211-1MGInVivoMAb anti-human CD1aOKT-6IgG1in vitro CD1a blockade, Flow cytometryBE0083IP0070
BE0213-1MGInVivoMAb anti-mouse CSF1R (CD115)AFS98IgG2a, κin vivo macrophage depletion, in vitro CSF1R neutralization, in vivo monocyte depletion, Flow cytometry, Western blotBE0089IP0070
BE0214-1MGInVivoMAb anti-mouse Thy1.1 (CD90.1)19E12IgG2a, κin vivo T cell depletionBE0085IP0070
BE0216-1MGInVivoMAb anti-human YB-121A3IgG1Immunohistochemistry (paraffin), Western blotBE0083IP0070
BE0218-1MGInVivoMAb anti-mouse Galectin-9RG9-1IgG2b, κin vivo Galectin-9 blockade in vitro Galectin-9 blockadeBE0090IP0070
BE0220-1MGInVivoMAb anti-mouse CD209b (SIGN-R1)22D1IgG, κin vivo SIGN-R1 blockade, Immunohistochemistry (frozen), Western blot, , Flow cytometryBE0091IP0070
BE0222-1MGInVivoMAb anti-rat FcRn heavy chain heterodimers1G3IgG1Immunofluorescence, ELISA, Flow cytometryBE0083IP0070
BE0223-1MGInVivoMAb anti-mouse CD8β (Lyt 3.2)53-5.8IgG1, κin vivo CD8+ T cell depletion, in vitro CD8 blockade, ImmunofluorescenceBE0088IP0070
BE0224-1MGInVivoMAb anti-human CD32 (FcγRIIA)IV.3IgG2bin vivo FcγRIIA blockade in humanized mice, in vitro FcγRIIA blockade, ELISA, , Flow cytometryBE0086IP0070
BE0225-1MGInVivoMAb anti-mouse TIM-4RMT4-54IgG2a, κin vitro TIM-4 blocking, Immunofluorescence, Flow cytometryBE0089IP0070
BE0228-1MGInVivoMAb anti-mouse MHC Class I (H-2Kk, H-2Dk)16-1-2N (HB14)IgG2aFunctional assays, Flow cytometryBE0085IP0070
BE0231-1MGInVivoMAb anti-human CD3UCHT1 (Leu-4) (T3)IgG1, κin vivo T cell depletion in humanized mice, ex vivo T cell inhibition for xenographs, Flow cytometryBE0083IP0070
BE0232-1MGInVivoMAb anti-mouse CD29KMI6IgG2a, κin vitro CD29 neutralization, Immunofluorescence, Flow cytometryBE0089IP0070
BE0233-1MGInVivoMAb anti-mouse IL-12 p75R2-9A5IgG2b, κin vivo IL-12p75 neutralization, ELISABE0090IP0080
BE0234-1MGInVivoMAb anti-human IL-12 p7020C2IgG1, κFunctional assays, ELISA, Flow cytometryBE0088IP0070
BE0235-1MGInVivoMAb anti-human IFNγB133.5IgG1in vivo IFNγ neutralization in humanized mice, in vitro IFNγ neutralizationBE0083IP0070
BE0236-1MGInVivoMAb anti-mouse Podoplanin (gp38)8.1.1IgGin vivo PDPN blockade, in vitro PDPN blockade, Immunofluorescence, Western blot, Flow cytometryBE0087IP0070
BE0237-1MGInVivoMAb anti-mouse IL-18YIGIF74-1G7IgG2a, κin vivo IL-18 neutralization, in vitro IL-18 neutralizationBE0089IP0070
BE0238-1MGInVivoMAb anti-human c-myc9E10IgG1Western blot, ELISA, Immunoprecipitation, Flow cytometryBE0083IP0070
BE0239-1MGInVivoMAb anti-mouse 4-1BB (CD137)3H3IgG2ain vivo 4-1BB stimulation, in vitro 4-1BB stimulationBE0089IP0070
BE0240-1MGInVivoMAb anti-human IL-4MP4-25D2IgG1, κin vitro IL-4 neutralization, Flow cytometryBE0088IP0070
BE0241-1MGInVivoMAb anti-mouse IFNAR-1MAR1-5A3IgG1, κin vivo IFNAR-1 blockade, in vitro IFNAR-1 blockade, Western blotBE0083IP0070
BE0243-1MGInVivoMAb anti-mouse IL-1αALF-161IgGin vivo IL-1α neutralization, in vitro IL-1α neutralizationBE0091IP0070
BE0244-1MGInVivoMAb anti-mouse/rat/rabbit TNFαTN3-19.12IgG, κin vivo TNFα neutralization, Flow cytometryBE0091IP0070
BE0245-1MGInVivoMAb anti-human IFNγB27IgG1Flow cytometryBE0083IP0070
BE0246-1MGInVivoMAb anti-mouse/rat IL-1βB122IgGin vivo IL-1β neutralization, in vitro IL-1β neutralization, ELISABE0091IP0070
BE0247-1MGInVivoMAb anti-mouse TNFR2 (CD120b)TR75-54.7IgGin vivo TNFR2 blockade, in vitro TNFR2 blockadeBE0091IP0070
BE0248-1MGInVivoMAb anti-human CD289.3IgG2ain vitro T cell stimulation/activationBE0085IP0070
BE0249-1MGInVivoMAb anti-mouse CXCR3 (CD183)CXCR3-173IgGin vivo CXCR3 neutralization, Flow cytometryBE0091IP0070
BE0250-1MGInVivoMAb anti-rat IgG1RG11/39.4IgG2c, κFlow cytometryBE0366IP0070
BE0251-1MGInVivoMAb anti-rat IgG2aRG7/1.30IgG2b, κImmunofluorescence, ELISA, Flow cytometryBE0086IP0070
BE0252-1MGInVivoMAb anti-rat IgG2bRG7/11.1IgG2b, κELISA, Flow cytometryBE0086IP0070
BE0256-1MGInVivoMAb anti-mouse IL-1 R (CD121a)JAMA-147IgG, κin vivo IL-1 R blockade, in vitro IL-1 R blockadeBE0091IPT060
BE0257-1MGInVivoMAb anti-mouse TCR Vγ1.1/Cr42.11IgGin vivo Vγ1 TCR+ cell depletion, Flow cytometryBE0091IP0070
BE0258-1MGInVivoMAb anti-mouse IL-21R4A9IgG2a, κin vivo IL-21R blockadeBE0089IP0070
BE0259-1MGInVivoMAb anti-mouse GM-CSFMP1-22E9IgG2a, κin vivo GM-CSF neutralization, in vitro GM-CSF neutralization, Flow cytometryBE0089IP0070
BE0260-1MGInVivoMAb Armenian hamster IgG isotype control, anti-glutathione S-transferasePIPIgGIP0070
BE0261-1MGInVivoMAb anti-mouse CD3εKT3IgG2ain vitro T cell negative selection, in vitro T cell stimulation/activation, ImmunofluorescenceBE0089IP0070
BE0262-1MGInVivoMAb anti-human CD44Hermes-1IgG2a, κin vivo CD44 blockade in xenografts, in vitro CD44 blockade, Western blot, ImmunofluorescenceBE0089IP0070
BE0270-1MGInVivoMAb anti-mouse CD47 (IAP)MIAP301IgG2a, κin vivo CD47 blockade, in vitro CD47 blockade, ImmunofluorescenceBE0089IP0070
BE0271-1MGInVivoMAb anti-mouse CD132 (common γ chain)3E12IgG2bin vivo γc blockade, Functional assays, Immunoprecipitation, Flow cytometryBE0090IP0070
BE0272-1MGInVivoMAb anti-mouse CD122 (IL-2Rβ)5H4IgG2a, κin vitro NK cell negative selection, Immunoprecipitation, Flow cytometryBE0089IP0070
BE0273-1MGInVivoMAb anti-mouse PD-1 (CD279)29F.1A12™IgG2ain vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Immunohistochemistry (frozen), Immunofluorescence, Western blot, Flow cytometryBE0089IP0070
BE0274-1MGInVivoMAb anti-mouse TIGIT1G9IgG1, κin vivo TIGIT stimulation, Flow cytometryBE0083IP0070
BE0275-1MGInVivoMAb anti-mouse TIM-3 (CD366)B8.2C12IgG1, κin vivo TIM-3 neutralization, in vitro TIM-3 blocking, Flow cytometryBE0088IP0070
BE0276-1MGInVivoMAb anti-human/monkey CD202H7IgG2b, κin vivo B cell depletion in hCD20 Tg mice, Immunohistochemistry (frozen), Immunoprecipitation, Flow cytometryBE0086IP0070
BE0277-1MGInVivoMAb anti-human/rat HER2 (neu)7.16.4IgG2a, κin vivo HER2/neu inhibition, in vitro HER2/neu inhibition, Immunoprecipitation, Immunofluorescence, Flow cytometryBE0085IP0070
BE0278-1MGInVivoMAb anti-human EGFR225 (HB-8508)IgG1in vitro EGFR blockade, in vivo EGFR blockade in xenografts, Western blot, Functional assaysBE0083IP0070
BE0280-1MGInVivoMAb anti-mouse c-Kit (CD117)2B8IgG2b, κFlow cytometry, Immunofluorescence, ImmunohistochemistryBE0090IP0070
BE0281-1MGInVivoMAb anti-human CD194G7IgG1Flow cytometry, Functional assays, Immunofluorescence, Chimeric antigen receptor construction (see Poirot, L., et al. reference)BE0083IP0070
BE0282-1MGInVivoMab anti-mouse IL-3MP2-8F8IgG1in vivo IL-3 neutralization, in vitro IL-3 neutralization, in vivo IL-3 receptor stimulation (as a complex with IL-3), ELISA, Flow cytometryBE0088IP0065
BE0283-1MGInVivoMAb anti-mouse/human/rat CD47 (IAP)MIAP410IgG1, κin vivo CD47 blockade, in vitro CD47 blocking, ImmunofluorescenceBE0083IP0070
BE0285-1MGInVivoMAb anti-human PD-L1 (B7-H1)29E.2A3IgG2b, κin vitro PD-L1 blockade, Functional assays, Immunohistochemistry (frozen), Flow cytometryBE0086IP0070
BE0287-1MGInVivoMAb anti-mouse IFNγRα (CD119)2E2IgGWestern blot, Immunoprecipitation, Flow cytometryBE0091IP0070
BE0288-1MGInVivoMAb anti-human CD4RPA-T4IgG1, κin vitro CD4 blockade, in vitro blocking of CD4+ T cell activation, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometryBE0083IP0070
BE0289-1MGInVivoMAb anti-mouse TIM-1 (CD365)3B3IgG2a, κin vivo TIM-1 activation, in vitro T cell stimulation/activation, Functional assays, ELISA, Flow cytometryBE0089IP0070
BE0290-1MGInVivoMAb rat IgG1 Isotype control, anti-trinitrophenolTNP6A7IgG1, λIP0070
BE0291-1MGInVivoMAb anti-human/monkey CD28CD28.2IgG1, κin vitro T cell stimulation/activation, Immunoprecipitation, Flow cytometry, Immunohistochemistry (frozen)BE0083IP0070
BE0292-1MGInVivoMAb anti-human/monkey CD40L (CD154)5C8IgG2ain vitro blocking of CD40/CD40L signaling, in vivo blocking of CD40/CD40L signaling, Immunoprecipitation, Flow cytometryBE0085IP0070
BE0293-1MGInVivoMAb anti-mouse c-Kit (CD117)ACK2IgG2bin vivo mast cell depletion, in vivo c-Kit+ cell depletion, in vitro c-Kit neutralization, Immunoprecipitation, Flow cytometryBE0090IP0070
BE0294-1MGInVivoMAb anti-mouse E-selectin (CD62E)9A9IgG2bin vivo E-selectin blockade, in vitro E-selectin blockade, Immunohistochemistry (frozen)BE0090IP0070
BE0296-1MGInVivoMAb anti-mouse 4-1BB (CD137)17B5IgGin vitro 4-1BB blockade, Flow cytometryBE0087IP0070
BE0297-1MGInVivoMAb human IgG1 isotype controlhuman IgG1IgG1, κIP0070
BE0298-1MGInVivoMAb anti-mouse CD122 (IL-2Rβ)TM-Beta 1IgG2b, κin vivo NK cell depletion, in vivo CD122 blockade, in vitro IL-2R blockade, Functional assays, Flow cytometryBE0090IP0080
BE0299-1MGInVivoMAb anti-mouse CD200 (OX2)OX-90IgG2a, κin vivo CD200 blockade, in vitro CD200 blockade, Immunohistochemistry (frozen), Immunofluorescence, Flow cytometryBE0089IP0070
BE0300-1MGInVivoMAb anti-mouse CD45.2104.2IgG2a, κFlow cytometry, in vivo CD45.2 blockade, in vitro CD45.2 blockade, Immunohistochemistry (frozen)BE0085IP0070
BE0301-1MGInVivoMAb human IgG2 isotype controlhuman IgG2IgG2, λIP0070
BE0302-25MGInVivoMAb anti-mouse CD20AISB12IgG2a, κFlow cytometry, Western blot, Not recommended for in vivo B cell depletionBE0089IP0070
BE0303-1MGInVivoMAb anti-mouse IL-17FMM17F8F5.1A9IgG1, κin vivo IL-17F neutralizationBE0083IP0070
BE0304-1MGInVivoMAb anti-mouse BTLA (CD272)6F7IgG1, κin vivo BTLA+ B cell and CD4 T cell depletion*, Flow cytometry, *see description for detailsBE0083IP0070
BE0305-1MGInVivoMAb anti-mouse CLEC9A (CD370)7H11IgG1, κin vivo CLEC9A blockade, in vivo Ag targeting to CLEC9A+ DCs, Western blot, ELISA, Immunoprecipitation, Immunofluorescence, Flow cytometryBE0088IP0070
BE0306-1MGInVivoMAb anti-human/monkey MHC class II (HLA-DR)L243IgG2a, κin vitro blocking of MHC class II HLA-DR, HLA class II binding assay, in vitro MHC class II HLA-DR expressing cell negative selection, Western blot, Flow cytometryBE0085IP0070
BE0307-1MGInVivoMAb anti-mouse CD16/CD322.4G2IgG2b, κin vitro Fc receptor blocking, in vivo Fc receptor blockingBE0090IP0080
BE0308-1MGInVivoMAb anti-rat CD4OX-38IgG2a, κin vivo CD4+ T cell depletion, Flow cytometryBE0085IP0070
BE0309-1MGInVivoMAb anti-mouse CXCL9 (MIG)MIG-2F5.5IgG, κin vivo CXCL9 neutralization, ImmunofluorescenceBE0091IP0070
BE0310-1MGInVivoMAb anti-mouse VISTA13F3IgGin vivo blocking of VISTA signaling, in vitro blocking of VISTA signalingBE0091IP0070
BE0311-1MGInVivoMAb anti-mouse CD317 (BST2, PDCA-1)927IgG2b, κin vivo pDC depletion, Immunofluorescence, Flow cytometryBE0090IP0070
BE0312-1MGInVivoMAb anti-mouse IFNγH22IgGin vivo IFNγ neutralization, in vitro IFNγ neutralizationBE0091IP0070
BE0313-10MGInVivoMAb anti-mouse IL-23 (p19)G23-8IgG1, κin vivo IL-23p19 neutralization, Western blotBE0088IP0070
BE0314-1MGInVivoMAb anti-mouse TIM-1 (CD365)3D10IgG1, κin vivo TIM-1 blockade, in vitro TIM-1 blockadeBE0088IP0070
BE0315-10MGInVivoMAb anti-mouse IL-15AIO.3IgG2a, λin vivo IL-15 neutralization, in vitro IL-15 neutralizationBE0089IP0070
BE0316-1MGInVivoMAb anti-mouse CCR3 (CD193)6S2-19-4IgG2b, λin vivo eosinophil depletionBE0090IP0070
BE0317-1MGInVivoMAb anti-mouse CD38NIMR5IgG2a, κin vivo CD38 stimulation, in vitro CD38 stimulation, in vitro B cell activation, Immunofluorescence, ELISA, Flow cytometryBE0089IP0070
BE0318-1MGInVivoMAb anti-human Ganglioside GD214G2aIgG2a, κin vitro induction of apoptosis in GD2+ cells, in vivo inhibition of GD2+ tumor cell growthBE0085IP0070
BE0319-1MGInVivoMAb anti-mouse FasL (CD178)MFL3IgGin vivo FasL blockade, In vitro FasL blockade, Functional assay, Immunohistochemistry (paraffin), Flow CytometryBE0091IP0070
BE0320-1MGInVivoMAb anti-mouse Ly6G/Ly6CNIMP-R14IgG2b, κin vivo neutrophil depletion, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Immunofluorescence, Flow cytometryBE0090IP0070
BE0321-1MGInVivoMAb anti-mouse NKG2A/C/E20D5IgG2a, κin vivo NKG2A blockade (see description), in vitro NKG2A blockade, Immunohistochemistry (frozen), Flow cytometryBE0089IP0070
BE0322-1MGInVivoMAb anti-mouse CD172a (SIRPα)P84IgG1, κin vivo SIRPα blocking, In vitro SIRPα blocking, Western blot, Immunoprecipitation, Flow cytometryBE0088IP0070
BE0323-1MGInVivoMAb anti-mouse TL1A (TNFSF15)5G4.6IgGin vivo TL1A neutralization, Flow cytometryBE0091IP0070
BE0324-1MGInVivoMAb anti-human/mouse denatured collagen type-I (RGD motif)XL313IgG1, κWestern blot, Immunofluorescence, in vivo administration (see description)
BE0325-1MGInVivoMAb anti-West Nile/dengue virus E proteinE60IgG2a, κNeutralization of WNV, Neutralization of DENV1,2,3,4BE0085IP0070
BE0326-1MGInVivoMAb anti-mouse IL-27 p28MM27.7B1IgG2a, κin vivo IL-27 p28 neutralization, in vitro IL-27 p28 neutralization, Flow cytometryBE0085IP0070
BE0327-1MGInVivoMAb anti-human IL-9MH9A4IgG2b, κFlow cytometry, ELISABE0086IP0070
BE0328-1MGInVivoMAb anti-mouse CD28D665IgG1, κin vivo T cell stimulation/activation, in vitro T cell stimulation/activationBE0083IP0070
BE0329-1MGInVivoMAb anti-mouse CD71 (TfR1)8D3IgG2ain vivo depletion of CD71+ cells, Immunofluorescence, Immunohistochemistry (frozen), Western blotBE0089IP0070
BE0330-1MGInVivoMAb anti-mouse CD69CD69.2.2IgG1, κin vivo down-regulation of CD69 expression, Functional assaysBE0083IP0070
BE0331-1MGInVivoMAb anti-rat/mouse CD71 (TfR1)OX-26IgG2a, κTargeted drug delivery to the brain, Immunohistochemistry (frozen), Flow cytometryBE0085IP0070
BE0332-1MGInVivoMAb anti-mouse FGL-1177R4IgG2a, κin vivo FGL-1 blockade, in vitro FGL-1 blockade, Flow cytometry, Immunohistochemistry (paraffin)BE0089IP0070
BE0333-1MGInVivoMAb anti-mouse/human/rat LRP1 (CD91)11H4IgG1, κWestern blot, Immunofluorescence, ImmunoprecipitationBE0083IP0070
BE0334-1MGInVivoMAb anti-mouse NKG2D (CD314)CX5IgG1, κin vivo NKG2D blockade, in vitro NKG2D blockade, Flow CytometryBE0088IP0070
BE0335-1MGInVivoMAb anti-human MAGE-C2 (CT10)LX-CT10.5IgG2a, κImmunohistochemistry (paraffin), Immunofluorescence, Western blotBE0085IP0070
BE0336-1MGInVivoMAb anti-human MUC1 (CD227)C595 (NCRC48)IgG3, κin vivo administration in mouse xenograft models, Immunohistochemistry (paraffin), Immunofluorescence, in vitro cell cytotoxicity assay, Western blotBE0093IP0070
BE0337-1MGInVivoMAb anti-mouse CD963.3IgG1, λin vivo CD96 blocking, in vitro CD96 blocking, Flow cytometryBE0088IP0070
BE0338-1MGInVivoMAb anti-human CD220 (Insulin Receptor)IR 83-22IgG1Western blotBE0083IP0070
BE0339-1MGInVivoMAb anti-mouse NKG2AB616A11IgG2b, κFlow cytometryBE0086IP0070
BE0340-1MGInVivoMAb anti-human/monkey MDR-1 (CD243)UIC2IgG2a, κin vivo MDR-1 blocking/depletion in xenogeneic murine, tumor models, in vitro MDR-1 blocking, Immunohistochemistry (paraffin)BE0085IP0070
BE0341-1MGInVivoMAb anti-human EphA2B2D6IgG2b, κImmunohistochemistry (paraffin), Immunoprecipitation, Functional assayBE0086IP0070
BE0342-1MGInVivoMAb recombinant Flt-3L-Ig (hum/hum)Flt-3L Fc-G1IP0070
BE0343-1MGInVivoMAb anti-human CD71 (TfR)5E9C11IgG1, κWestern blot, Immunoprecipitation, Flow cytometryBE0083IP0070
BE0344-1MGInVivoMAb anti-mouse TIM-4F31-5G3IgG1, κFlow cytometryBE0088IP0070
BE0345-1MGInVivoMAb anti-mouse/rat/bovine VLDL-RIgG-6A6IgG1, λWestern blotBE0083IP0070
BE0346-1MGInVivoMAb anti-mouse CD326 (EpCAM)G8.8IgG2a, κImmunohistochemistry (frozen), Immunofluorescence, Flow cytometry, Western blotBE0089IP0070
BE0347-1MGInVivoMAb anti-human CSF1R (CD115)2-4A5-4IgG1, κin vitro CSF1R neutralization, Immunohistochemistry (paraffin), Functional assays, Flow cytometryIP0070
BE0348-1MGInVivoMAb anti-mouse CD27RM27-3E5IgG2a, κin vivo CD27 stimulation, in vitro CD27 stimulation, Immunoprecipitation, Flow cytometryBE0089IP0070
BE0350-1MGInVivoMAb anti-mouse/human PrP (prion protein)TW1IgG2ain vivo PrP blocking, Western blotBE0085IP0070
BE0351-1MGInVivoMAb anti-human NKG2D (CD314)1D11IgG1, κin vitro NKG2D blocking, Immunoprecipitation, Flow cytometryBE0083IP0070
BE0352-1MGInVivoMAb anti-mouse E-Cadherin (CD324)DECMA-1IgG1, κin vivo E-Cadherin neutralization, In vitro E-Cadherin neutralization, Immunofluorescence, Immunoprecipitation, Western blotBE0088IP0070
BE0353-1MGInVivoMAb anti-mouse/human/rat/monkey ICOS (CD278)C398.4AIgGin vitro T cell stimulation/activation, Flow cytometry, ImmunoprecipitationBE0091IP0070
BE0354-1MGInVivoMAb anti-human CD2CB.219IgG2b, κin vivo CD2 blockade in huCD2tg miceBE0086IP0070
BE0355-1MGInVivoMAb anti-human CA19-91116-NS-19-9IgG1, κImmunohistochemistry (paraffin), Immunofluorescence, Flow cytometryBE0083IP0070
BE0356-1MGInVivoMAb anti-mouse CD20MB20-11IgG2c, κin vivo B cell depletion, Western blotBE0366IP0070
BE0357-1MGInVivoMAb anti-SARS-CoV-2 S protein (RBD epitope A)SARS2-01IgG1, κin vitro blocking of SARS-CoV-2 S protein, Flow cytometry, ELISABE0083IP0070
BE0358-1MGInVivoMAb anti-SARS-CoV-2 S protein (NTD)SARS2-29IgG1, κFlow cytometry, ELISABE0083IP0070
BE0359-1MGInVivoMAb anti-SARS-CoV-2 S protein (RBD epitope B)SARS2-34IgG1, κin vitro blocking of SARS-CoV-2 S protein, Flow cytometry, ELISABE0083IP0070
BE0360-1MGInVivoMAb anti-mouse CD24M1/69IgG2b, κin vivo administration, Immunohistochemistry (frozen), Immunohistochemistry (paraffin), Immunofluorescence, Flow cytometryBE0090IP0070
BE0361-1MGInVivoMAb anti-mouse PD-L1 (B7-H1)10F.2H11IgG2b, κin vivo blocking of PD-L1/CD80 (B7-1) interactions, in vitro blocking of PD-L1/CD80 (B7-1) interactions, ELISA, Flow cytometryBE0090IP0070
BE0362-1MGInVivoMAb anti-human CEACAM 1/3/5/6/86G5jIgG1, κWestern blot, ELISA, Immunofluorescence, Immunohistochemistry (paraffin), Flow cytometryBE0083IP0070
BE0363-1MGInVivoMAb anti-human CEACAM7P3-7BIgG1, κWestern blot*, ELISA*, Immunoprecipitation*, Immunohistochemistry*, Flow cytometry*, *Based on unpublished dataBE0083IP0070
BE0364-1MGInVivoMAb anti-mouse BTLA (CD272)HMBT-6B2IgGin vivo BTLA blockade, Flow cytometryBE0091IP0070
BE0365-1MGInVivoMAb anti-mouse CD80 (B7-1)RM80IgG2ain vivo CD80 blockade, in vitro CD80 blockade, Flow cytometryBE0089IP0070
BE0366-1MGInVivoMAb mouse IgG2c isotype control, anti-dengue virusDV5-1IgG2c, κIP0070
BE0367-1MGInVivoMAb anti-human CD71 (TfR1)B3/25IgG1, κin vitro CD71 targeting, in vivo CD71 targeting, ImmunofluorescenceBE0083IP0070
BE0368-1MGInVivoMAb anti-human/mouse/rat amyloid-betaMOAB-2IgG2b, λWestern blot, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, ELISABE0086IP0070
BE0370-1MGInVivoMAb anti-human CD71 (TfR1)T56/14IgG1, κFlow cytometry, ImmunoprecipitationBE0083IP0070
BE0371-1MGInVivoMAb anti-mouse IL-12 p35C18.2IgG2a, κin vivo IL-12 p35 neutralization, in vitro IL-12 p35 neutralization, ELISA, ImmunoprecipitationBE0089IP0070
BE0372-1MGInVivoMAb anti-mouse osteopontin (SPP1)100D3IgG2c, κin vivo OPN neutralization, in vitro OPN neutralization, ELISABE0366IP0070
BE0374-1MGInVivoMAb anti-mouse FAP73.3IgG1, κChimeric antigen receptor construction, Flow cytometryBE0083IP0070
BE0375-1MGInVivoMAb anti-human EGFR425IgG2a, κin vivo EGFR blockade in xenografts, in vitro EGFR blockade, ImmunoprecipitationBE0085IP0070
BE0376-1MGInVivoMAb anti-human CD71 (TfR1)2C1IgG2b, κFlow cytometry*, Immunoprecipitation*, Western blot*, *Based on unpublished dataBE0086IP0070
BE0377-1MGInVivoMAb anti-mouse CD31 (PECAM-1)390IgG2a, κin vivo CD31 blocking, Intravital imaging, Immunofluorescence, Flow cytometryBE0089IP0070
BE0378-1MGInVivoMAb anti-mouse CD16.2 (FcγRIV)9E9IgGin vivo CD16.2 blockade, in vitro CD16.2 blockade, Flow cytometryBE0091IP0070
BE0379-1MGInVivoMAb anti-mouse TSLP28F12IgG2a, κin vivo TSLP neutralization, in vitro TSLP neutralizationBE0089IP0070
BE0380-1MGInVivoMAb anti-human c-Kit (CD117)SR-1IgG2a, κin vivo c-Kit+ cell depletion, in vitro c-Kit targeting, Immunohistochemistry (frozen)BE0085IP0070
BE0381-1MGInVivoMAb anti-human GM-CSFBVD2-21C11IgG2a, κImmunofluorescence, ELISA, Flow cytometryBE0089IP0070
BE0382-1MGInVivoMAb anti-mouse/human/rat osteopontin (SPP1)MPIIIB10IgG1, κin vivo OPN neutralization, in vitro OPN neutralization, Immunohistochemistry (paraffin), Western blotBE0083IP0070
BE0383-1MGInVivoMAb anti-mouse/human/rat PD-L1368A.4H1Mouse IgG1, κin vivo PD-L1 blockade , in vitro PD-L1 blockade , Flow cytometryBE0083IP0070
BE0384-1MGInVivoMAb anti-human GM-CSFBVD2-23B6IgG2a, κin vitro GM-CSF neutralization, ELISABE0089IP0070
BE0385-1MGInVivoMAb anti-mouse DKK3DKK3-4.22IgG1, κin vivo DKK3 blocking, in vitro DKK3 blocking, Western blot, Flow cytometry,BE0083IP0070
BE0386-1MGInVivoMAb anti-human CD326 (EpCAM)Ber-EP4IgG1, κImmunohistochemistry (paraffin), Immunofluorescence, Flow cytometry, ImmunoprecipitationBE0083IP0070
BE0387-1MGInVivoMAb anti-mouse/human phosphorylated PD-1 (CD279)407.6G12IgG2a, κWestern Blot, Flow CytometryBE0085IP0070
BE0388-1MGInVivoMAb anti-human CD71 (TfR1)BK19.9IgG1, κImmunohistochemistry (frozen)BE0083IP0070
BE0389-1MGInVivoMAb anti-canine CD341H6IgG1, κImmunohistochemistry (frozen), Flow cytometry, Western blot,BE0083IP0070
BE0391-1MGInVivoMAb anti-human MUC16VK8Mouse IgG1, κFlow cytometry, Western blotBE0083IP0070
BE0392-1MGInVivoMAb anti-mouse myeloperoxidase (MPO)6G4IgG2c, κin vivo administration, in vitro administration, Immunofluorescence, ,BE0366IP0070
BE0394-1MGInVivoMAb anti-mouse IL-252C3IgG1, κin vivo IL-25 neutralizationBE0083IP0070
BE0395-1MGInVivoMAb anti-mouse/human Mac-2 (Galectin-3)M3/38 (TIB-166)IgG2a, κWestern blot, Immunofluorescence, Immunohistochemistry (paraffin), Immunoprecipitation,BE0089IP0070
BE0396-1MGInVivoMAb anti-human/mouse GRP78C38IgG2b, κin vivo GRP78 blockade, in vitro GRP78 blockade, Western blot, Flow cytometry, ,BE0086IP0070
BE0398-1MGInVivoMAb anti-mouse CD83Michel-17IgG1, κin vivo CD83 engagement, in vitro CD83 blockade, Flow cytometry, ELISA,BE0088IP0070
BE0399-1MGInVivoMAb anti-mouse VEGF-A2G11-2A05IgG2a, κin vivo VEGF-A neutralization, Western blot,BE0089IP0070
BE0400-1MGInVivoMAb anti-mouse RGMb307.9D1IgG2a, κin vivo RGMb blockade, ELISA, Flow cytometry, ,BE0089IPT060
BE0401-1MGInVivoMAb anti-human CEACAM54H11-8IgG1, κ, ,BE0083IP0070
BE0402-1MGInVivoMAb anti-human GPC-2CT3IgG1, κ, ,BE0083IP0070
BE0403-1MGInVivoMAb anti-mouse CD966A6/CD96IgG2a, λBE0089IP0070
BE0404-1MGInVivoMAb anti-human GPC3YP7IgG1, κ, ,BE0083IP0070
BE0406-1MGInVivoMAb anti-human CD2LO-CD2aIgG2b, κ, ,BE0090IP0070
BE0407-1MGInVivoMAb anti-human Fy3MIMA-29IgG2a, κ, ,BE0085IP0070
BE0408-1MGInVivoMAb anti-human TROP-2Pr1E11IgG1, κWestern blot, Immunohistochemistry (frozen), Flow cytometry, ,BE0083IP0070
BE0409-1MGInVivoMAb anti-human BRCA1BR64IgG1, κ, ,BE0083IP0070
BE0410-1MGInVivoMAb anti-human EphA2SHM16IgG1, κBE0083IP0070
BE0411-1MGInVivoMAb anti-human GC1q R (C1QBP)60.11IgG1, κ, ,BE0083IP0070
BE0412-1MGInVivoMAb anti-human GPC3HS20IgG1, κ, ,CP174IP0070
BE0413-1MGInVivoMAb anti-rat TCR α/βR73IgG1, κin vivo administrationBE0083IP0070
BE0414-1MGInVivoMAb anti-rat TCR γ/δV65IgG1, κin vivo γ/δ T cell depletion, Flow cytometryBE0083IP0070
BE0415-1MGInVivoMAb anti-rat CD8αOX-8IgG1, κin vivo CD8+ T cell depletion, Flow cytometry, Immunohistochemistry (paraffin), Immunohistochemistry (frozen)BE0083IP0070
BE0416-1MGInVivoMAb anti-human/mouse GRP78N88IgG1, κin vivo administration, Functional assaysBE0083IP0070
BE0417-1MGInVivoMAb anti-rat CD2OX-34IgG2a, κin vivo CD2 blockade, in vitro CD2 blockade, Western blotBE0085IP0070
New (1/3/2024)BE0418-1MGInVivoMAb anti-rat CD28JJ316IgG1, κin vivo T cell stimulation/activationBE0083IP0070
New (1/18/2024)BE0419-1MGInVivoMAb anti-rat IL-4OX-81IgG1, κin vivo IL-4 neutralization, ELISA, Flow cytometryBE0083IP0070
New (2/2/2024)BE0420-1MGInVivoMAb anti-mouse CD205 (DEC-205)NLDC-145IgG2a, κin vivo antigen-targeting to DEC-205, in vitro antigen-targeting to DEC-205, Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry,BE0089IP0070
New (2/26/2024)BE0421-1MGInVivoMAb anti-chikungunya virus E2CHK-265IgG2c, λViral entry and egress inhibitionBE0366IP0070
New (3/5/2024)BE0422-1MGInVivoMAb anti-mouse CD86 (B7-2)2D10IgG2b, κImmunoprecipitation, Flow cytometry, Functional assays,BE0090IP0070
BP0001-1-5MGInVivoPlus anti-mouse CD3ε145-2C11IgG1in vivo T cell depletion, in vitro T cell stimulation/activation, Immunofluorescence, Flow cytometry, Western blotBP0091IP0070
BP0003-1-5MGInVivoPlus anti-mouse CD4GK1.5IgG2b, κin vivo CD4+ T cell depletion, Flow cytometry, Western blotBP0090IP0065
BP0004-1-5MGInVivoPlus anti-mouse CD8α53-6.7IgG2a, κin vivo CD8+ T cell depletion, Immunofluorescence, Flow cytometry, Western blotBP0089IP0065
BP0012-5MGInVivoPlus anti-mouse CD25 (IL-2Rα)PC-61.5.3IgG1, λin vivo regulatory T cell depletion, Flow cytometryBP0088IP0070
BP0016-2-5MGInVivoPlus anti-mouse CD40FGK4.5/FGK45IgG2ain vivo CD40 activation, in vitro B cell stimulation/activationBP0089IP0070
BP0017-1-5MGInVivoPlus anti-mouse CD40L (CD154)MR-1IgGin vivo blocking of CD40/CD40L signaling, in vitro blocking of CD40/CD40L signaling, Western blotBP0091IP0070
BP0031-5MGInVivoPlus anti-mouse OX40 (CD134)OX-86IgG1, κin vivo OX40 activation, in vitro OX40 activation, Western blotBP0088IP0070
BP0032-5MGInVivoPlus anti-mouse CTLA-4 (CD152)UC10-4F10-11IgGin vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Flow cytometry, Western blotBP0091IP0065
BP0033-2-5MGInVivoPlus anti-mouse PD-1 (CD279)J43IgGin vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Western blotBP0091IP0065
BP0036-5MGInVivoPlus anti-mouse NK1.1PK136IgG2a, κin vivo NK cell depletion, Flow cytometryBP0085IP0070
BP0045-5MGInVivoPlus anti-mouse IL-411B11IgG1, κin vivo IL-4 neutralization, in vitro IL-4 neutralization, in vivo IL-4 receptor stimulation (as a complex with IL-4), Flow cytometry, Western blotBP0088IP0070
BP0050-5MGInVivoPlus anti-mouse IL-10R (CD210)1B1.3AIgG1, κin vivo blocking of IL-10/IL-10R signaling, in vitro blocking of IL-10R signaling, Flow cytometry, Western BlotBP0088IPT065
BP0051-5MGInVivoPlus anti-mouse IL-12 p40C17.8IgG2a, κin vivo IL-12p40 neutralization, p40 affinity chromatography, Immunoprecipitation, ELISA, Flow cytometry, Western blotBP0089IP0070
BP0055-5MGInVivoPlus anti-mouse IFNγXMG1.2IgG1, κin vivo IFNγ neutralization, in vitro IFNγ neutralization, ELISPOT, Flow cytometry, Western blotBP0088IPT080
BP0057-5MGInVivoPlus anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-β1D11.16.8IgG1, κin vivo TGFβ neutralization, in vitro TGFβ neutralization, Western blotBP0083IP0070
BP0058-5MGInVivoPlus anti-mouse TNFαXT3.11IgG1in vivo TNFα neutralization, in vitro TNFα neutralization, Western blotBP0088IP0080
BP0060-5MGInVivoPlus anti-mouse VEGFR-2DC101IgG1, κin vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling, Western blotBP0088IP0070
BP0061-5MGInVivoPlus anti-mouse CD8α2.43IgG2b, κin vivo CD8+ T cell depletion, Western blotBP0090IP0070
BP0063-5MGInVivoPlus anti-mouse GITRDTA-1IgG2b, λin vivo GITR stimulationBP0090IP0070
BP0066-5MGInVivoPlus anti-mouse Thy1.2 (CD90.2)30H12IgG2b, κin vivo ILC depletion, in vivo T cell depletion, Western blotBP0090IP0070
BP0075-5MGInVivoPlus anti-mouse Ly6G/Ly6C (Gr-1)RB6-8C5IgG2b, κin vivo depletion of Gr-1+ myeloid cells, Flow cytometry, Immunohistochemistry (paraffin), Immunohistochemistry (frozen)BP0090IP0070
BP0075-1-5MGInVivoPlus anti-mouse Ly6G1A8IgG2a, κin vivo neutrophil depletion, in vivo MDSC depletion, Immunofluorescence, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Flow cytometryBP0089IP0070
BP0079-5MGInVivoPlus anti-human MHC Class I (HLA-A, HLA-B, HLA-C)W6/32IgG2a, κFunctional assaysBP0085IP0065
BP0083-5MGInVivoPlus mouse IgG1 isotype control, unknown specificityMOPC-21IgG1, κIP0065
BP0085-5MGInVivoPlus mouse IgG2a isotype control, unknown specificityC1.18.4IgG2a, κIP0070
BP0086-5MGInVivoPlus mouse IgG2b isotype control, unknown specificityMPC-11IgG2b, κIP0070
BP0087-5MGInVivoPlus polyclonal Syrian hamster IgGpolyclonal Syrian hamster IgGIgGIP0070
BP0088-5MGInVivoPlus rat IgG1 isotype control, anti-horseradish peroxidaseHRPN-CP167IgG1, κIP0070
BP0089-5MGInVivoPlus rat IgG2a isotype control, anti-trinitrophenol2A3IgG2a, κIP0065
BP0090-5MGInVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyaninLTF-2-CP166IgG2b, κIP0070
BP0091-5MGInVivoPlus polyclonal Armenian hamster IgGpolyclonal Armenian hamster IgGIgGIP0070
BP0099-5MGInVivoPlus recombinant CTLA-4-Ig (hum/hum)CTLA-4-Ig (hum/hum)IP0070
BP0101-5MGInVivoPlus anti-mouse PD-L1 (B7-H1)10F.9G2™IgG2b, κin vivo PD-L1 blockade, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometry, Western blotBP0090IP0065
BP0115-5MGInVivoPlus anti-mouse TIM-3 (CD366)RMT3-23IgG2a, κin vivo TIM-3 neutralization, in vitro TIM-3 blocking, Flow cytometryBP0089IP0070
BP0117-5MGInVivoPlus anti-mouse CD8αYTS 169.4IgG2b, κin vivo CD8+ T cell depletion, Western blotBP0090IP0070
BP0131-5MGInVivoPlus anti-mouse CTLA-4 (CD152)9H10IgGin vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Western blotBP0087IP0070
BP0146-5MGInVivoPlus anti-mouse PD-1 (CD279)RMP1-14IgG2a, κin vivo blocking of PD-1/PD-L signalingBP0089IP0070
BP0164-5MGInVivoPlus anti-mouse CTLA-4 (CD152)9D9IgG2bin vivo CTLA-4 neutralization, Western blotBP0086IP0070
BP0169-5MGInVivoPlus anti-mouse 4-1BB (CD137)LOB12.3IgG1, κin vivo activation of 4-1BBBP0088IP0080
BP0173-5MGInVivoPlus anti-mouse IL-17A17F3IgG1, κin vivo IL-17A neutralizationBP0083IP0070
BP0174-5MGInVivoPlus anti-mouse LAG-3C9B7WIgG1, κin vivo LAG-3 neutralization, in vitro LAG-3 neutralization, Flow cytometry, Western blotBP0088IP0070
BP0175-5MGInVivoPlus anti-mouse CD71 (TfR1)R17 217.1.3/TIB-219IgG2a, κin vivo depletion of CD71+ cellsBP0089IP0070
BP0213-5MGInVivoPlus anti-mouse CSF1R (CD115)AFS98IgG2a, κin vivo macrophage depletion, in vitro CSF1R neutralization, in vivo monocyte depletion, Flow cytometry, Western blotBP0089IP0070
BP0239-5MGInVivoPlus anti-mouse 4-1BB (CD137)3H3IgG2ain vivo 4-1BB stimulation, in vitro 4-1BB stimulationBP0089IP0070
BP0241-5MGInVivoPlus anti-mouse IFNAR-1MAR1-5A3IgG1, κin vivo IFNAR-1 blockade, in vitro IFNAR-1 blockade, Western blotBP0083IP0070
BP0273-5MGInVivoPlus anti-mouse PD-1 (CD279)29F.1A12™IgG2ain vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Immunohistochemistry (frozen), Immunofluorescence, Western blot, Flow cytometryBP0089IP0070
BP0274-5MGInVivoPlus anti-mouse TIGIT1G9IgG1, κin vivo TIGIT stimulation, Flow cytometryBP0083IP0070
BP0283-5MGInVivoPlus anti-mouse/human/rat CD47 (IAP)MIAP410IgG1, κin vivo CD47 blockade, in vitro CD47 blocking, ImmunofluorescenceBP0083IP0070
BP0290-5MGInVivoPlus rat IgG1 isotype control, anti-trinitrophenolTNP6A7IgG1, λIP0070
BP0297-5MGInVivoPlus human IgG1 isotype controlhuman IgG1IgG1, κIP0070
BP0301-5MGInVivoPlus human IgG2 isotype controlhuman IgG2IgG2, λIP0070
BP0307-5MGInVivoPlus anti-mouse CD16/CD322.4G2IgG2b, κin vitro Fc receptor blocking, in vivo Fc receptor blockingBP0090IP0080
BP0308-5MGInVivoPlus anti-rat CD4OX-38IgG2a, κin vivo CD4+ T cell depletion, Flow cytometryBP0085IP0070
BP0310-5MGInVivoPlus anti-mouse VISTA13F3IgGin vivo blocking of VISTA signaling, in vitro blocking of VISTA signalingBP0091IP0070
BP0329-5MGInVivoPlus anti-mouse CD71 (TfR1)8D3IgG2ain vivo depletion of CD71+ cells, Immunofluorescence, Immunohistochemistry (frozen), Western blotBP0089IP0070
BP0356-5MGInVivoPlus anti-mouse CD20MB20-11IgG2c, κin vivo B cell depletion, Western blotBE0366IP0070
BP0366-5MGInVivoPlus mouse IgG2c isotype control, anti-dengue virusDV5-1IgG2c, κIP0070
CP001-1MGRecombiMAb anti-mouse PD-L1 (B7-H1) (D265A)10F.9G2™-CP001IgG1, κin vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot*, *Reported for the original rat IgG2b 10F.9G2 antibodyCP047IP0070
CP002-1MGRecombiMAb anti-mouse PD-1 (CD279) (D265A)RMP1-14-CP002IgG1, κin vivo blocking of PD-1/PD-L signaling*, *Reported for the original rat IgG2a RMP1-14 antibodyCP047IP0070
CP004-1MGRecombiMAb anti-mouse PD-1 (CD279)29F.1A12™-CP004IgG1, κin vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, Immunohistochemistry (frozen)*, Immunofluorescence*, Western blot*, Flow cytometry*, *Reported for the original rat IgG2a 29F.1A12 antibody,BP0083IP0070
CP005-1MGRecombiMAb anti-mouse PD-1 (CD279) (D265A)29F.1A12™-CP005IgG1, κin vivo blocking of PD-1/PD-L signaling* , in vitro PD-1 neutralization* , Immunohistochemistry (frozen)* , Immunofluorescence* , Western blot* , Flow cytometry* , *Reported for the original rat IgG2a 29F.1A12 antibody ,CP047IP0070
CP006-1MGRecombiMAb anti-mouse CTLA-4 (CD152)9D9-CP006IgG1, κin vivo CTLA-4 neutralization*, Western blot*, *Reported for the original mouse IgG2b 9D9 antibodyBP0083IP0070
CP008-1MGRecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)9D9-CP008IgG2a, κin vivo CTLA-4 neutralization*, Western blot*, *Reported for the original mouse IgG2b 9D9 antibodyCP048IP0070
CP013-1MGRecombiMAb anti-mouse LAG-3 (D265A)C9B7W-CP013IgG1, κin vivo LAG-3 neutralization*, in vitro LAG-3 neutralization*, Flow cytometry*, Western blot*, *Reported for the original rat IgG1 C9B7W antibodyCP047IP0070
CP014-1MGRecombiMAb anti-mouse LAG-3C9B7W-CP014IgG2a, κin vivo LAG-3 neutralization*, in vitro LAG-3 neutralization*, Flow cytometry*, Western blot*, *Reported for the original rat IgG1 C9B7W antibodyBP0085IP0070
CP017-1MGRecombiMAb anti-mouse OX40 (CD134)OX86-CP017IgG2a, κin vivo OX40 activation*, in vitro OX40 activation*, Western blot*, *Reported for the original rat IgG1 OX-86 antibodyBP0085IP0070
CP018-1MGRecombiMAb anti-mouse OX40 (CD134) (LALA-PG)OX86-CP018IgG2a, κin vivo OX40 activation*, in vitro OX40 activation*, Western blot*, *Reported for the original rat IgG1 OX-86 antibodyCP048IP0070
CP025-1MGRecombiMAb anti-mouse CD16/CD322.4G2-CP025IgG2a, κin vitro Fc receptor blocking*, in vivo Fc receptor blocking*, *Reported for the original rat IgG2b 2.4G2 antibodyBP0085IP0070
CP026-1MGRecombiMAb anti-mouse CD16/CD32 (LALA-PG)2.4G2-CP026IgG2a, κin vitro Fc receptor blocking*, in vivo Fc receptor blocking*, *Reported for the original rat IgG2b 2.4G2 antibodyCP048IP0070
CP027-1MGRecombiMAb anti-mouse GITR (D265A)DTA-1-CP027IgG1, κin vivo GITR stimulation*, *Reported for the original rat IgG2b DTA-1 antibodyCP047IP0070
CP028-1MGRecombiMAb anti-mouse GITRDTA-1-CP028IgG2a, κin vivo GITR stimulation*, *Reported for the original rat IgG2b DTA-1 antibodyBP0085IP0070
CP029-1MGRecombiMAb anti-mouse GITR (LALA-PG)DTA-1-CP029IgG2a, κin vivo GITR stimulation*, *Reported for the original rat IgG2b DTA-1 antibodyCP048IP0070
CP032-1MGRecombiMAb anti-mouse CD40L (CD154) (D265A)MR-1-CP032IgG1, κin vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, Western blot*, *Reported for the original Armenian hamster IgG MR-1 antibodyCP047IP0070
CP033-1MGRecombiMAb anti-mouse CD40L (CD154)MR-1-CP033IgG2a, κin vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, Western blot*, *Reported for the original Armenian hamster IgG MR-1 antibodyBP0085IP0070
CP034-1MGRecombiMAb anti-mouse CD40L (CD154) (LALA-PG)MR-1-CP034IgG2a, κin vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, Western blot*, *Reported for the original Armenian hamster IgG MR-1 antibodyCP048IP0070
CP038-1MGRecombiMAb anti-mouse 4-1BB (CD137) (LALA-PG)LOB12.3-CP038IgG2a, κin vivo activation of 4-1BB*, *Reported for the original rat IgG1 LOB12.3 antibodyCP048IP0070
CP039-1MGRecombiMAb anti-mouse 4-1BBL (CD137L) (D265A)TKS-1-CP039IgG1, κin vivo 4-1BBL blockade*, ELISA*, *Reported for the original rat IgG2a TKS-1 antibodyCP047IP0070
CP040-1MGRecombiMAb anti-mouse 4-1BBL (CD137L)TKS-1-CP040IgG2a, κin vivo 4-1BBL blockade*, ELISA*, *Reported for the original rat IgG2a TKS-1 antibodyBP0085IP0070
CP041-1MGRecombiMAb anti-mouse 4-1BBL (CD137L) (LALA-PG)TKS-1-CP041IgG2a, κin vivo 4-1BBL blockade*, ELISA*, *Reported for the original rat IgG2a TKS-1 antibodyCP048IP0070
CP042-1MGRecombiMAb anti-mouse CD28D665-CP042IgG2a, κin vivo T cell stimulation/activation*, in vitro T cell stimulation/activation*, *Reported for the original mouse IgG1 D665 antibodyBP0085IP0070
CP043-1MGRecombiMAb anti-mouse CD28 (LALA-PG)D665-CP043IgG2a, κin vivo T cell stimulation/activation*, in vitro T cell stimulation/activation*, *Reported for the original mouse IgG1 D665 antibodyCP048IP0070
CP044-1MGRecombiMAb anti-mouse ICOSL (CD275) (D265A)HK5.3-CP044IgG1, κin vivo ICOSL neutralization*, *Reported for the original rat IgG2a HK5.3 antibodyCP047IP0070
CP045-1MGRecombiMAb anti-mouse ICOSL (CD275)HK5.3-CP045IgG2a, κin vivo ICOSL neutralization*, *Reported for the original rat IgG2a HK5.3 antibodyBP0085IP0070
CP046-1MGRecombiMAb anti-mouse ICOSL (CD275) (LALA-PG)HK5.3-CP046IgG2a, κin vivo ICOSL neutralization*, *Reported for the original rat IgG2a HK5.3 antibodyCP048IP0070
CP047-1MGRecombiMAb mouse IgG1 (D265A) isotype control, anti-hen egg lysozymeN/A-CP047IgG1, κIP0070
CP048-1MGRecombiMAb mouse IgG2a (LALA-PG) isotype control, anti-hen egg lysozymeN/A-CP048IgG2a, κIP0070
CP049-1MGRecombiMAb mouse IgG2b (LALA-PG) isotype control, anti-hen egg lysozymeN/A-CP049IgG2b, κIP0070
CP127-1MGRecombiMAb anti-mouse CD4GK1.5-CP127IgG2b, κin vivo CD4+ T cell depletion* , Flow cytometry* , Western blot* , *Reported for the original rat IgG2b GK1.5 antibodyBP0086IP0065
CP128-1MGRecombiMAb anti-mouse CD8α2.43-CP128IgG2b, κin vivo CD8+ T cell depletion*, Western blot*, *Reported for the original rat IgG2b 2.43 antibodyBP0086IP0070
CP129-1MGRecombiMAb anti-mouse Ly6G1A8-CP129IgG2a, κin vivo neutrophil depletion*, in vivo MDSC depletion*, Immunofluorescence*, Immunohistochemistry (paraffin)*, Immunohistochemistry (frozen)*, Flow cytometry*, *Reported for the original rat IgG2a 1A8 antibodyBP0085IP0070
CP130-1MGRecombiMAb anti-mouse CD71 (TfR1)R17 217.1.3-CP130IgG2a, κin vivo depletion of CD71+ cells*, *Reported for the original rat IgG2a R17 217.1.3 antibodyBP0085IP0070
CP131-1MGRecombiMAb anti-mouse CSF1R (CD115)AFS98-CP131IgG2a, κin vivo macrophage depletion*, in vitro CSF1R neutralization*, in vivo monocyte depletion*, Flow cytometry*, Western blot*, *Reported for the original rat IgG2a AFS98 antibodyBP0085IP0070
CP132-1MGRecombiMAb anti-mouse VEGFR-2DC101-CP132IgG2a, κin vivo blocking of VEGF/VEGFR-2 signaling*, in vitro blocking of VEGFR signaling*, Western blot*, *Reported for the original rat IgG1 DC101 antibodyBP0085IP0070
CP133-1MGRecombiMAb anti-mouse CD40FGK4.5-CP133IgG2a, κin vivo CD40 activation*, in vitro B cell stimulation/activation*, *Reported for the original rat IgG2a FGK4.5 antibodyBP0085IP0070
CP134-1MGRecombiMAb anti-mouse CD8αYTS 169.4-CP134IgG2a, κin vivo CD8+ T cell depletion*, Western blot*, *Reported for the original rat IgG2b YTS 169.4 antibodyBP0085IP0070
CP135-1MGRecombiMAb anti-mouse Ly6G/Ly6C (Gr-1)RB6-8C5-CP135IgG2a, κin vivo depletion of Gr-1+ myeloid cells*, Flow cytometry*, Immunohistochemistry (paraffin)*, Immunohistochemistry (frozen)*, *Reported for the original rat IgG2b RB6-8C5 antibodyBP0085IP0070
CP146-5MGRecombiMAb anti-mouse CTLA-4 (CD152)9H10-CP146IgG1, κin vivo CTLA-4 neutralization*, in vitro CTLA-4 neutralization*, Western blot, *Reported for the original Syrian hamster IgG 9H10 antibodyBP0083IP0070
CP147-100MGRecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozymeN/A-CP147IgG4, κIP0070
CP148-1MGRecombiMAb human IgG4 S228P L235E P329G (SPLEPG) isotype control, anti-hen egg lysozymeN/A-CP148IgG4IP0070
CP149-1MGRecombiMAb human IgG1 (LALA-PG) isotype control, anti-hen egg lysozymeN/A-CP149IgG1IP0070
CP150-1MGRecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozymeN/A-CP150IgG2aIP0070
CP151-1MGRecombiMAb anti-mouse PD-1 (CD279) (D265A)RMP1-14-CP151IgG2a, κin vivo blocking of PD-1/PD-L signaling*, *Reported for the original rat IgG2a RMP1-14 antibodyCP150IP0070
CP152-1MGRecombiMAb human IgG4 (S228P) isotype control, anti-respiratory syncytial virusPalivizumab-CP152IgG4, κIP0070
CP153-1MGRecombiMAb anti-mouse PD-1 (CD279) (LALA-PG)RMP1-14-CP153IgG2a, κin vivo blocking of PD-1/PD-L signaling*, *Reported for the original rat IgG2a RMP1-14 antibodyCP150IP0070
CP154-1MGRecombiMAb anti-mouse PD-L1 (B7-H1) (LALA-PG)10F.9G2™-CP154IgG2a, κin vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot*, *Reported for the original rat IgG2a 10F.9G2™ antibodyCP048IP0070
CP155-1MGRecombiMAb anti-mouse PD-1 (CD279) (LALA-PG)29F.1A12™-CP155IgG2a, κin vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, Immunohistochemistry (frozen)*, Immunofluorescence*, Western blot*, Flow cytometry*, *Reported for the original rat IgG2a 29F.1A12 antibody,CP156IP0070
CP156-1MGRecombiMAb mouse IgG2a (LALA-PG) isotype control, unknown specificityMOPC-21-CP156IgG2a, κIP0070
CP157-5MGRecombiMAb anti-mouse PD-1 (CD279)RMP1-14-CP157IgG2a, κin vivo blocking of PD-1/PD-L signaling*, *Reported for the original rat IgG2a RMP1-14 antibodyBP0085IP0070
CP160-1MGRecombiMAb mouse IgG2a isotype control, unknown specificityMOPC-21-CP160IgG1, κin vivo LAG-3 neutralization*, in vitro LAG-3 neutralization*, Flow cytometry*, Western blot*, *Reported for the original rat IgG1 C9B7W antibodyIP0070
CP161-1MGRecombiMAb human IgG1 (LALA-PG) isotype control, anti-respiratory syncytial virusPalivizumab-CP161IgG1IP0070
CP162-5MGRecombiMAb anti-mouse PD-1 (CD279)RMP1-14-CP162IgG1, κin vivo blocking of PD-1/PD-L signaling*, *Reported for the original rat IgG2a RMP1-14 antibodyBP0083IP0070
CP168-5MGRecombiMAb anti-mouse PD-L1 (B7-H1)10F.9G2™-CP168IgG1, κin vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot*, *Reported for the original rat IgG2a RMP1-14 antibodyBP0083IP0070
CP169-1MGRecombiMAb human IgG1 isotype control, anti-respiratory syncytial virusPalivizumab-CP169IgG1, κIP0070
CP171-1MGRecombiMAb human IgG1 (N297A) isotype control, anti-hen egg lysozymeN/A-CP171IgG1, κIP0070
New (1/19/2024)CP172-1MGRecombiMAb anti-mouse Ly6G/Ly6C (Gr-1)RB6-8C5-CP172IgG2b, κin vivo depletion of Gr-1+ myeloid cells*, Flow cytometry*, Immunohistochemistry (paraffin)*, Immunohistochemistry (frozen)*, *Reported for the original rat IgG2b RB6-8C5 antibodyBP0086IP0070
CP173-1MGRecombiMAb human IgG1 (D265A) isotype control, anti-hen egg lysozymeN/A-CP173IgG1IP0070
CP174-1MGRecombiMAb human IgG1 isotype control, anti-hen egg lysozymeN/A-CP174IgG1, κIP0070
New (1/19/2024)CP175-1MGRecombiMAb human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozymeN/A-CP175IgG1, κIP0070
IP0065-50MLInVivoPure pH 6.5 Dilution Buffer
IP0070-50MLInVivoPure pH 7.0 Dilution Buffer
IP0080-50MLInVivoPure pH 8.0 Dilution Buffer
IPT060-50MLInVivoPure pH 6.0T Dilution Buffer
IPT065-50MLInVivoPure pH 6.5T Dilution Buffer
IPT080-50MLInVivoPure pH 8.0T Dilution Buffer
RT0263-1MGReadyTag anti-c-myc9E10IgG1Western blot, ELISA, Immunoprecipitation, Flow cytometryIP0070
RT0264-1MGReadyTag anti-GSTF50-3D12.2IgG1Western blotIP0070
RT0265-1MGReadyTag anti-GFPF56-6A1.2.3IgG2bWestern blot, ImmunofluorescenceIP0070
RT0266-1MGReadyTag anti-6-His6-HisIgG1Western blot, Immunoprecipitation, ImmunofluorescenceIP0070
RT0267-1MGReadyTag anti-OVAF2-3.58IgG1IP0070
RT0268-1MGReadyTag anti-HA12CA5IgG2bELISA, Western blot, Immunoprecipitation, ImmunofluorescenceIP0070
RT0269-1MGReadyTag anti-DDDDKAP1501IgG2bWestern blot, Immunoprecipitation, ImmunofluorescenceIP0070
SIM0001-1MGInVivoSIM anti-human TNFα (Adalimumab Biosimilar)AdalimumabIgG1TNFα neutralization, Flow Cytometry, ELISA, Immunofluoresence, Immunoprecipitation, Immunohistochemistry, Western BlotCP174IP0070
SIM0002-1MGInVivoSIM anti-human EGFR (Cetuximab Biosimilar)CetuximabIgG1EGFR blockade, ELISA, Flow CytometryCP174IP0070
SIM0003-1MGInVivoSIM anti-human PD-1 (Nivolumab Biosimilar)NivolumabIgG4Blocking of PD-1/PD-L signaling, Flow Cytometry, Immunohistochemistry, Western BlotCP147IP0070
SIM0004-1MGInVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar)IpilimumabIgG1CTLA-4 neutralization, Flow Cytometry, ELISA, Western BlotCP174IP0070
SIM0005-1MGInVivoSIM anti-human HER2 (Trastuzumab Biosimilar)TrastuzumabIgG1Flow Cytometry, ELISA, Immunohistochemistry, Western BlotCP174IP0070
SIM0006-1MGInVivoSIM anti-human TNFα (Infliximab Biosimilar)InfliximabIgG1TNFα neutralization, Flow Cytometry, ELISA, Western BlotCP174IP0070
SIM0007-1MGInVivoSIM anti-human VEGF (Bevacizumab Biosimilar)BevacizumabIgG1VEGF neutralization , , Flow Cytometry , , ELISA , , Immunoprecipitation , , Western BlockCP174IP0070
SIM0008-1MGInVivoSIM anti-human CD20 (Rituximab Biosimilar)RituximabIgG1Flow Cytometry , , ELISA , , Western BlotCP174IP0070
SIM0009-1MGInVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar)AtezolizumabIgG1Flow Cytometry, Western BlotCP171IP0070
SIM0010-1MGInVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar)PembrolizumabIgG4Blocking of PD-1/PD-L signaling, Functional assaysCP147IP0070
SIM0011-1MGInVivoSIM anti-human C5 (Eculizumab Biosimilar)EculizumabIgG4Inhibition of the activation of C5, Functional assays, ELISA, ImmunoprecipitationCP147IP0070
SIM0012-1MGInVivoSIM anti-human VEGFR-2 (Ramucirumab Biosimilar)RamucirumabIgG1Functional assays, Immunohistochemistry, Flow cytometryCP174IP0070
SIM0013-1MGInVivoSIM anti-human IL-17A (Secukinumab Biosimilar)SecukinumabIgG1Functional assays, ELISA, Immunofluoresence, Immunohistochemistry, Flow CytometryCP174IP0070
SIM0014-1MGInVivoSIM anti-human IL-6R (Tocilizumab Biosimilar)TocilizumabIgG1Functional assays, ELISACP174IP0070
SIM0015-1MGInVivoSIM anti-human LAG-3 (Relatlimab Biosimilar)RelatlimabIgG4, κELISACP147IP0070
SIM0016-1MGInVivoSIM anti-human IgE (Omalizumab Biosimilar)OmalizumabIgG1, κIgE neutralization , , Flow cytometry , , ELISACP174IP0070
SIM0017-1MGInVivoSIM anti-human NGF (Tanezumab Biosimilar)TanezumabIgG2, κNGF neutralization , , ELISABP0301IP0070
SIM0018-1MGInVivoSIM anti-human integrin α4β1 (VLA-4)NatalizumabHuman IgG4, κFunctional assays , Flow cytometryBE0092IP0070
SIM0019-1MGInVivoSIM anti-human HER2 (Pertuzumab Biosimilar)PertuzumabHuman IgG1, κFunctional assays, ELISA, NeutralizationCP174IP0070
SIM0020-1MGInVivoSIM anti-human IL-12 p40 (Ustekinumab Biosimilar)UstekinumabIgG1, κFunctional assays,CP174IP0070
SIM0021-1MGInVivoSIM anti-human PD-L1 (Avelumab Biosimilar)AvelumabIgG1, λFunctional assays, ELISA, in vitro PD-L1 blockadeCP169IP0070
SIM0022-1MGInVivoSIM anti-human IFNAR1 (Anifrolumab Biosimilar)AnifrolumabIgG1, κFunctional assays, Western blot, ELISACP175IP0070
SIM0023-1MGInVivoSIM anti-human IL-4Rα (CD124) (Dupilumab Biosimilar)DupilumabIgG4, κFunctional assays,CP147IP0070
SIM0024-1MGInVivoSIM anti-human integrin α4β7 (LPAM-1) (Vedolizumab Biosimilar)VedolizumabIgG1, κFunctional assays, ELISA, Western blot,CP149IP0070
SIM0025-1MGInVivoSIM anti-human IL-23 (p19) (Guselkumab Biosimilar)GuselkumabIgG1, λIL-23p19 neutralization, Functional assays, ELISA, Western blot,CP169IP0070
SIM0026-1MGInVivoSIM anti-human Claudin 18.2 (Zolbetuximab Biosimilar)ZolbetuximabIgG1, κFunctional assays, ,CP174IP0070
SIM0027-1MGInVivoSIM anti-human PD-L1 (Durvalumab Biosimilar)DurvalumabIgG1, κELISA, Flow Cytometry, Western Blot, Functional assaysCP149IP0070
SIM0028-1MGInVivoSIM anti-human RANKL (CD254) (Denosumab Biosimilar)DenosumabIgG1, κFunctional assays, Flow Cytometry,CP174IP0070
SIM0029-1MGInVivoSIM anti-human IL-17A (Ixekizumab Biosimilar)IxekizumabIgG4, κFunctional assays, ELISA, Immunofluorescence, Flow Cytometry, Western blotCP147IP0070
SIM0030-1MGInVivoSIM anti-human IL-6 (Siltuximab Biosimilar)SiltuximabIgG1, κFunctional assays, ELISA,CP174IP0070
SIM0031-1MGInVivoSIM anti-human nectin-4 (Enfortumab Biosimilar)EnfortumabIgG1, κFunctional assays, ELISA, Western blotCP174IP0070
New (1/3/2024)SIM0032-1MGInVivoSIM anti-human amyloid-beta (Lecanemab Biosimilar)LecanemabIgG1, κFunctional assaysCP174IP0070

調査無料Search for reagent suppliers

試薬の入手でお困りではありませんか?
供給元を無料で調査いたします
お問い合わせはお気軽に
下記のお問い合わせフォームから
お問い合わせの事例をご参考にご覧ください